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ABSTRACT 
In the United States, older individuals (≥65 years), account for about 34% of healthcare 
expenditures with women accounting for 22% greater expenditure than men. Musculoskeletal 
disease and disability alone costs nearly $950 billion/year. Over 40% of older women (≥70 
years) live with disability and/or functional limitations. These gender differences suggest the role 
of gender specific factors. In addition to greater lifetime risk of chronic diseases like arthritis, 
depression and osteoporosis, women are more likely to accumulate greater allostatic load from 
physiological insults and dysregulation across the reproductive life course. Together, these 
factors could increase the risk of functional limitations and disability in older women. However, 
our current understanding of the effect of women’s reproductive health (menarche, parity, 
breastfeeding, menopause, hysterectomy and oophorectomy) on age related structural and 
functional changes is limited. Understanding these associations could have significant public 
health implications on disability prevention in later life. 
Through this dissertation, we assessed the associations of reproductive factors across the 
life course, with physical function decline, risk of hip osteoarthritis (OA) and changes in hip 
geometry in later life. We found that women with early life reproductive factors like later age at 
menarche, greater parity and breastfeeding were more likely to maintain their grip strength in 
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later life. These findings are likely due to lifestyle factors associated with child rearing. In 
contrast, same cohort of women demonstrated associations between greater parity and 
breastfeeding with lower risk of radiographic hip OA. These findings maybe attributable to 
pregnancy related changes at the hip joint. In a cohort of midlife women, early life reproductive 
factors including older age at first birth, and breastfeeding with associated with unfavorable 
levels and accelerated change in hip geometry measure during the menopausal transition (MT). 
Changes in Follicle Stimulating Hormone (FSH) and Sex Hormone Binding Globulin (SHBG) 
were associated with poorer hip geometry levels and accelerated its change during the MT. Put 
together, the 3 studies demonstrated associations between early life reproductive health and 
musculoskeletal structure and function in later life. Future understanding of underlying 
mechanisms could help design targeted interventions to prevent disability in later life. 
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1.0  SPECIFIC AIMS 
In the United States, individuals 65 and older, account for about 34% of healthcare 
expenditures with nearly 6% projected average growth in Medicare utilization for 2018-19. On 
average, women spent 22% more than men1. Musculoskeletal disease and disability alone cost 
nearly $950 billion/year2. More than 40% of women aged 70 or older, suffer from some form of 
disability and poor physical function3. Women live longer with disability, thus a compromised 
quality of life4. The gender gap in disability suggests the role of gender specific factors. Women 
are subject to greater risk of chronic diseases like arthritis, osteoporosis, and depression5. In 
addition, greater predisposition to disability and functional decline may be related to socio-
behavioral factors like education, smoking, and physical activity6,7. However, these factors only 
account for part of the gender gap in disability. Interestingly, our current understanding of the 
effect of women’s reproductive life [from menarche to menopause] on age related changes in the 
bone and muscle is limited. With the rapidly aging population8 and the increasing disability rates, 
it is of utmost importance to improve the quality of life ensure successful aging of older women.  
The overall objective is to improve our understanding of the relationships of reproductive 
and hormonal factors with changes in musculoskeletal structure and functioning in later life. Our 
central hypothesis is that reproductive history and hormonal changes in women affects 
musculoskeletal health with increasing age. Our hypothesis is based on results from studies 
exploring the associations between reproductive factors and other age-related diseases. A large 
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Norwegian study showed that both early and later age at menarche were associated with an 
increased risk of mortality9. Similarly, extremes of parity were associated with an increased risk 
of cardiovascular disease10 and mortality11. Fewer years of menstruation was associated with 
increased risk of fractures12. While the effects of reproductive health on some chronic diseases 
and mortality are well known, the relationship between reproductive health and musculoskeletal 
aging remains to be understood. The proposed research attempts to enhance our understanding of 
the role of reproductive health on changes in muscle function and bone geometry with age. The 
rationale for the proposed research is to identify modifiable and non-modifiable reproductive 
factors that impact the age-related bone and muscle changes. This is important to designing 
appropriate interventions and prevention of functional limitation and disability in women. We 
believe our findings shall help to identify “poor” reproductive factors [characterized by early age 
at menarche, nulliparity, non-breastfeeding, oral contraceptive use, early age at menopause, 
hysterectomy or oophorectomy and shorter length of reproductive life] that prevent functional 
decline and disability later in life.  
To test our central hypothesis and achieve our overall objective, our specific aims were: 
Aim 1: Evaluate association between reproductive factors and physical function in 
later life 
We hypothesize that poor reproductive factors will be associated with lower physical 
function levels and faster decline in physical function in older women.  
Aim 2: Determine the association between reproductive factors and risk of hip 
osteoarthritis  
We hypothesize that poor reproductive factors will be associated with greater odds of 
prevalent and incident hip osteoarthritis in older women. 
3 
Aim 3: Assess the association between reproductive factors and hip geometry in 
midlife women 
We hypothesize that at risk reproductive health and sex steroid hormone levels will be 
associated with worse hip geometry in later life and greater changes in hip geometry across the 
menopausal transition.  
As an outcome of this dissertation, we expect to identify the specific reproductive factors 
[Figure 1] and quantify independently, their effect on musculoskeletal aging characterized by 
physical function decline (Aim 1), risk of osteoarthritis (Aim 2) and change in hip geometry 
(Aim 3). The dissertation uses data from the Study of Osteoporotic Fractures (SOF) cohort and 
Study of Women’s health Across the Nation(SWAN). Through this dissertation, we hope to 
improve current understanding of the overall aging process by identifying the reproductive 
factors contributing to successful aging. 
 
Figure 1-1: Conceptual model for the study 
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2.0  BACKGROUND AND SIGNIFICANCE 
2.1 AGING POPULATION OF WOMEN  
Aging has been defined as the time dependent decline in function13. In 2012, 8% (562 
million) of the world’s population were aged 65 or older14. In United States, the population of 
individuals aged 65 and over was estimated to be 46 million in 2014. That is, 1 in 7 individuals 
were 65 or older, forming 14.5% of the population.  With the aging of the baby boomers, the 
older (≥ 65 years) population is rising and is projected to double to over 98 million by the year 
2060 (accounting for 25% of the population)15. With the increase in life expectancy, the gender 
gap has widened. As of 2014, average life expectancy at age 65 was 20.5 years for females and 
18 years for males15. This is reflected in the sex ratio of 127 women for every 100 men 65 or 
older. At age 85 or older, this ratio increases to 192 women per 100 men. 
However, the Center for Disease Control (CDC) estimates that nearly 22% of the elderly 
individuals (≥65 years) have fair to poor health, and about 7% of them require help with personal 
care16. With the increasing economical and healthcare burden of this population, it becomes 
important to understand the many factors contributing to successful aging. While prior research 
and healthcare had been largely focused on increasing the lifespan of an individual, in the recent 
years the view has become more robust, with focus on preventing decline in health17, 
maintenance of function and social well-being and therefore, “successful aging”. 
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2.2 SUCCESSFUL AGING 
Many definitions for “successful aging” have been put-forth. However, the components 
of what constitutes “successful aging” is yet to be completely understood. In 1961, Havighurst 
defined “successful aging” as not only increasing the life span but also the satisfaction from 
life18. Rowe and Kahn revised this to distinguish between “successful aging” and “normal 
aging”, defining “successful aging” and high social, physical and cognitive functioning as well 
as being free from disability19.  They further explained “successful aging” to consist of 3 
components - low probability of disability and disease, high physical and cognitive function and 
an active engagement with life [figure 2]20. While this model is largely accepted, being disease 
free in older age is not realistic18. Therefore, this definition has been modified to include those 
with minimal disease and disability, i.e., individuals with high levels of physical function21-23. 
 
Figure 2-1: Successful aging model (Rowe and Kahn) 
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Despite the many definitions, the concept of “successful aging” aims to maximize the functional 
status of an individual, making them more self-reliant, and resilient. “Successful aging” may be 
achieved through a subtle balance of lowering the risk factors to adverse events and increasing 
resilience in its presence19. With an increasing population of older adults in the community, it 
has become increasingly important to understand the various factors which could promote 
“successful aging”.  
2.3 DISABILITY IN WOMEN 
One of the important components of successful aging is living free of disability. 
Functional limitations and disability produce a highly vulnerable population. In 2008, the US 
Department of commerce reported that approximately 19% of the population was living with 
some form of disability with 12% reporting severe disability24. The health expenditure associated 
with disability alone was estimated to be nearly $398 billion25. These levels are increasing with 
the aging population26. Women (24.4%) have higher prevalence of disability compared to men 
(19.8%)27. Studies have shown that 10-15% of women may be disabled as early as midlife (45 
years)28. Higher disability levels are associated with lower health related quality of life29. 
Individuals with disability are predisposed to greater risk of obesity30, physical inactivity31 and 
smoking32, all of which are associated with poor health and chronic diseases. Disability also 
increases the risk of death from heart diseases, cancers, stroke and suicides33. Conversely, 
chronic diseases also increase the risk of disability. However, at any level of comorbidity, 
women have greater disability34. Disability is also associated with socio-economic disparities. 
The prevalence of disability was greatest in American Indians (31%) and lowest in the Asian 
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(10.1%) population35. Thus, disability contributes greatly to the social, economic and healthcare 
burdens of the country. Women have greater life expectancy than men but spend greater 
proportion of life in disability36. With the increasing population of older women, there is an 
important need to understand and prevent the risk factors for disability. Although reproductive 
life is a major part of women’s life, very little is understood about its influence on later life 
health and the aging process. Through this dissertation, we expect to understand the effect of 
reproductive health on musculoskeletal aging in women. 
The Nagi model37 (1976), with modifications from Verbrugge & Jette38 (1994) still 
serves as the most well accepted models of the disability process. This model has been accepted 
by sociology and medical disciplines39, and preferred by the Institute of Medicine40. The model 
suggests an accumulation of pathology resulting in impairment and limitations.  These processes 
culminate in an individual’s ability to perform socially expected activities39, like adequate 
physical functioning. Therefore, understanding the pathological processes and risk factors 
leading to functional impairment, limitations or disability, shall help design appropriate disability 
prevention strategies. Through the course of this dissertation we aim to understand the risk of 
poor reproductive health on 3 musculoskeletal factors associated with current or future disability 
– decline in physical function, prevalence and incidence of hip osteoarthritis and change in hip 
geometry. Using a life course approach, we shall be able to assess and quantify individually the 
effect of these reproductive factors on musculoskeletal aging. 
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3.0  A LIFE COURSE APPROACH REPRODUCTIVE HEALTH AND DISEASE 
The concept of health and aging is multi-dimensional and dynamic41. In 1965, Dubos 
suggested that an important predictor of health is the ability of an organism to adapt to the 
immediate environment and its demands42. These demands change over the course of life, 
producing varied changes in the biology and physiology of an individual. In addition, these 
experiences prepare an individual for impending environmental needs. Therefore, the assessment 
of health and aging at a given point in life may not adequately reflect the true relationship 
between the two43. Many studies have demonstrated that the influences during early 
developmental periods i.e., intrauterine and post-natal periods bear a strong influence on the age-
related declines in later life44 for the mother and the child. A life-course approach is thus 
required. The life-course approach aims at understanding the associations between the social and 
biological exposures during fetal life, childhood and adult-life to the age-related changes in 
health and disease in later life45.  
Martin and Finch, described 6 stages in the life of an individual – developing (from fetal 
life to childhood), maturing, reproducing, sageing (intermediate between mature, reproducing 
adult to senescing adult stage, constantly adapting to the changing demands of the environment), 
senescing (phase of cognitive and functional decline) and dying44. The demands and exposures 
of each of these stages vary greatly, resulting in changes aimed at adaptation. Interestingly, each 
of these stages are inter-related and bear a significance in the overall well-being in later life. 
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Thus, understanding the components and effects of each of these stages on aging is important to 
the development of interventions for successful aging.   
The basis for life course epidemiology was set by David Barker in 199245. Barker 
proposed the Fetal Origins of Disease hypothesis - postulating that the diseases in adult life are 
outcomes of in-utero insults to the fetus, particularly nutrition45. As an extension, in 2002, the 
developmental origins of adult health and disease were proposed. Gluckman et al, hypothesized 
that early life events and environments, influenced the susceptibility to chronic diseases in later 
life46. The life course approach aims to understand the relationship between growth, plateau and 
degeneration phases of life47. 
3.1.1 Epidemiology of reproductive events 
While the changes in the reproductive system begin with the fetal life48, the period of 
active reproductive life does not begin till adolescence. The first menstrual period or menarche, 
marks the beginning of this reproductive period, which ends with the cessation of menstruation 
or menopause. The reproductive health of a woman is closely related to the overall physical and 
mental health. It is further characterized by events such as menstrual regularity, pregnancy, 
child-birth, lactation, successive pregnancies and other gynecological conditions, that have been 
known to yield valuable information regarding many subclinical diseases49. Besides genetic 
influences50, many social, behavioral and lifestyle factors influence the timing of these events.  
Across the world, the average age at menarche is between 12 - 13.5 years48,51. An early 
age at menarche is associated with low birth weight and faster growth during infancy52,53, 
paternal absence54, childhood sexual or physical abuse55, and childhood obesity56. Compared to 
breast fed children, girls who received formula feeds had an earlier age at menarche57. Study 
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from NHANES (from 1988-1994 and 1999-2002) reported a decline in age at menarche in both 
Non-Hispanic Whites (12.8 to 12.52 years) and Non-Hispanic Blacks (12.9 to 12.08). This 
decline was associated with higher BMI across ethnicities58. 
While the mean age at menopause is 51 years, it can range from 40-60 years59. Low 
socioeconomic status is associated with early age at menopause60. Menarche ≤ 11 years60, 
nulliparity60, and smoke exposure (prenatal or premenopausal)61, are associated with early 
menopause. It has been suggested that greater body fat may act as a source of estrone, thus 
delaying the age at menopause62. However, studies testing this hypothesis have shown 
inconsistent results. Some studies reporting later menopause in heavier women62,63, others have 
shown no association64. Interestingly, a longitudinal evaluation of BMI over the life course, 
showed no influence on age at menopause65. The Black women’s health study reported that BMI 
was inversely related to age at menopause in African American women66,67. However, a multi-
ethnic comparison showed no difference in age at natural menopause between Caucasian and 
African American women64. Similar inconsistencies have been noted with diabetes status as well. 
While some studies have reported Type 168 and Type 2 diabetes69 as independent predictors of 
early menopause, others have shown no association64,70. In addition to age at menarche and 
parity, younger age at first birth and older age at last birth, and longer duration of breastfeeding 
have been associated with later age at menopause71.  Reports from the United States72 (from 49.1 
years in 1915 to 50.5 years in 1969), Finland73, Sweden74, and across Europe75 have reported an 
increase in the age at menopause over the years. However, establishing a trend in age at 
menopause is limited by inconsistent definitions of menopause ranging from self-report to final 
menstrual period to biomarkers and 12 months of amenorrhea76. Thus, it is evident that the 
timing of these reproductive events serves as a marker of underlying social, behavioral and 
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overall well-being of an individual. While many of the reproductive factors are genetically 
determined, some factors like use of oral contraceptives, hormone therapy and breast feeding 
may be modifiable.  
3.1.2 Hormonal regulation of reproductive system 
Reproductive life in a woman is regulated by age and event specific hormonal changes 
regulated by the hypothalamo-pituitary ovarian axis [Figure. 4]. 
Figure 3-1: Regulation of hormones via Hypothalamo-Pituitary Ovarian (HPA) axis 
Gonadotropin Releasing Hormone (GnRH), secreted from the hypothalamus, stimulates 
the secretion of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). Both LH 
and FSH are dynamically regulated across the menstrual cycle77. FSH stimulates ovarian follicles 
and increases release of estradiol from the ovaries78. LH acts on the theca cells to aid in the 
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synthesis of androgens from cholesterol. In addition, LH is essential to ovulation. and corpus 
luteum formation. After ovulation, the corpus luteum (temporary endocrine organ from the 
luteinized granulosa cells], supported by LH, secretes progesterone to prepare endometrium for 
implantation of the ovum79. In the absence of fertilization, the corpus luteum function decreases 
leading to fall of progesterone levels and menstruation. Simultaneously, the estradiol levels rise 
and fall twice during the menstrual cycle. The first rise occurs in the mid-follicular level 
decreasing after ovulation subsequently rising again in the mid-luteal phase (parallel to rise in 
progesterone). Both estradiol and progesterone, with the hormone inhibin, regulate secretion and 
release of GnRH. Through negative feedback mechanism, estradiol lowers GnRH secretion 
while progesterone, along with estradiol reduces the frequency of GnRH pulses77.  
Menarche – GnRH secretion is temporarily active in early fetal life but remains dormant 
till the onset of puberty48. GnRH release and subsequent activation of the HPA axis play a 
crucial role in gonadal development and function. Serum leptin (a hormone produced from the 
fat tissue) levels may play a modulatory role on GnRH, to initiate puberty48. 
Pregnancy and lactation: Pregnancy and lactation are periods of suppressed ovulation78. 
Pregnancy is maintained by elevated levels of progesterone. First from the corpus luteum and 
subsequently from the placenta78,79. Concurrently, estradiol is produced from the placenta and 
fetal adrenal glands80,81. The levels of these hormones continue to rise throughout pregnancy82 
with estradiol levels decline rapidly following delivery82. The decline in estrogen and 
progesterone levels at delivery allows for action of prolactin on breast tissue, resulting in milk 
production83. Despite high FSH levels, inadequate LH stimulation during lactation leads to low 
levels of estrogen and subsequent amenorrhea84. During pregnancy, the body undergoes dramatic 
changes to accommodate for the increased metabolic demand85. This is characterized by increase 
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in visceral adipose tissue, insulin resistance and circulating lipids86. It is hypothesized that 
lactation helps mobilize this fat and thus re-setting the maternal metabolism and lowering risk of 
metabolic diseases87. 
Menopause: Although most of the ovarian follicles are lost in fetal life88, there is 
progressive loss during reproductive life89. This loss is exponentiated during menopausal 
transition90. Inhibin B is an early marker of ovarian aging. It regulates the steep increase in FSH 
compared to LH78. The increase in the levels of FSH is hallmark of the transition90. FSH levels 
increase drastically leading up to the menopausal transition and thereafter plateau91. Menopausal 
transition is characterized by onset of irregular and unpredictable cycles. Early menopausal 
transition may be associated with elevated estradiol92. This elevation may reflect augmented 
folliculogenesis and shorter follicular phase during the early menopausal transition89. Rapid 
decline in estradiol levels were noted starting 2 years before the final menstrual period and 
stabilizing around 2 years after91,93. More recent studies have demonstrated that such a pattern is 
not consistent in all women. Studies in the same cohort of women has demonstrated distinct 
trajectories of hormone change in E2 and FSH94. The E2 trajectory groups showed 4 distinct 
patterns of slow decline, flat, rise and steep decline or rise and slow decline. While FSH increase 
was more consistent, women showed 3 distinct trajectory patterns of low, medium or high rise 
across the MT94. With menopause, the ovarian production of testosterone also decreases. 
However, the concurrent drop in Serum Hormone Binding Globulin(SHBG) – the carrier protein 
(synthesized in the liver) for both estradiol and testosterone, offsets this decrease95. The decline 
in SHBG complements the decline in estradiol and increase in insulin resistance89. The 
mechanism that relates lower SHBG to lower insulin resistance is not clearly understood. 
Although independent of BMI96, higher liver fat could decrease SHBG production and impair 
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insulin sensitivity97. Decrease in SHBG and/or greater bioavailable T levels are associated with 
greater visceral fat98. However, adipose tissue could also facilitate activation of 
androstenedione99 leading to hyperandrogenesis98. Excess androgen [testosterone to estradiol 
ratio] has been shown to be associated with increased risk of metabolic syndrome over time100.  
It is thus evident that the reproductive events are characterized by a subtle balance of the 
many hormones in the body. Thus, reproductive events and factors serve as underlying markers 
of health at a given time of life. It is plausible that reproductive events and sex hormones are 
early life marker for musculoskeletal health in later life. Complex hormonal, biomechanical, 
inflammatory and socio-behavioral factors may mediate the associations between reproductive 
events, sex hormones and musculoskeletal aging. 
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4.0  POTENTIAL MECHANISMS RELATING REPRODUCTIVE HEALTH TO 
MUSCULO-SKELETAL HEALTH 
4.1 HORMONAL PATHWAY 
4.1.1 Muscle and physical function 
The timing and type of reproductive factors may produce different impact to adapt to the 
concurrent needs of the body functioning and environment101. Across reproductive health, the 
exposure to levels of hormones particularly estrogen, progesterone and testosterone vary. Studies 
have shown that these hormones may act independently102-105 or along with other hormones106 to 
affect physical functioning. A meta-analysis of 23 studies demonstrated that post-menopausal 
women receiving Hormone Therapy (HT) had nearly 5% greater muscle strength compared to 
women not receiving HT107. The authors indicated that HT improved the functioning of the 
muscle by improving the muscle quality108. These findings are supported by molecular studies in 
rats. Compared to rats with intact ovary, ovariectomized rats produced 20% lower specific force 
from the permeabilized fibers of the soleus muscles. Conversely, supplementation of estradiol to 
ovariectomized rodents restored muscle protein (myosin) function to control levels109. The 
authors hypothesized that the lack of sex-steroid hormones potentially resulted in a decrease in 
force generating protein crossbridges109. Together with the variation in hormones across life, it is 
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possible to hypothesize a cumulative role of hormone affecting muscle strength in later life. 
Pregnancy is associated with increased levels of both estrogen and progesterone. High levels of 
progesterone can alter the effect of estrogen in the body110 by blocking estrogen receptors111. 
Therefore, the effect of higher cumulative exposure to estrogen with greater parity, may be 
altered through high levels of progesterone. In addition, breast feeding reduces the synthesis of 
estrogen112 and progesterone113 while increasing the levels of follicle stimulating hormone111. 
These changes in hormones could have lasting effects on muscle structure and function. The 
rapid decline in estrogen may have negative effects on muscle health114. Decrease in the estrogen 
levels during menopause may be associated with Vitamin D deficiency115. Vitamin D deficiency 
subsequently leads to muscle weakness116. Decrease in estrogen is also related to an increase in 
oxidative stress, and decrease in insulin sensitivity, growth hormone, Insulin like Growth Factor-
1 (IGF-1), all of which have been related to low muscle mass in women117. Variation in 
hormones over time could thus lead to significant changes in muscle mass and strength. 
Accumulation of these insults and changes across the life course could result in disability and 
functional limitations in later life. 
4.1.2 Joint and osteoarthritis
Both weight bearing and non-weight bearing joints in the body are affected by OA, 
suggesting the role of systemic factors118. In addition to its effect on muscle mass and function, 
estrogen could have direct impact on the joints118. This is supported by postmenopausal 
increased risk of OA119 and presence of estrogen receptors in the joint tissue120. Both mice and 
rabbit models have shown an increased cartilage and bone turnover after completion of sexual 
maturation121. In rabbits’ removal of ovaries was associated with increased osteoarthritic 
17 
damage, further supporting the role of female hormones in the structure and functioning of the 
musculoskeletal system122. Such a post-maturational increase in risk of OA was also noted in 
humans. Nearly 65% of women with knee OA had osteoarthritic symptoms starting from 
perimenopause to 5 years after menopause (natural or hysterectomy)123. Post-menopausal women 
with radiologically confirmed OA had low levels of estradiol and hydroxyestrone (a metabolite 
of estradiol)124. Together, it is possible that the changes in estradiol over the life course many 
bear significant impact on the joint tissue, manifesting as OA in later life.  
4.1.3 Bone 
The effect of hormones on bone metabolism is well established. Estrogen plays an 
important role in the development and remodeling of the bones125. Estrogen increases osteoblast 
cell numbers and promote bone formation. A decline in estrogen is associated with greater bone 
resorption with increased osteoclastic activity, thus increasing the risk of osteoporosis126 and 
subsequent fractures. Bone loss begins around the 3rd decade of life127, but is accelerated during 
the menopausal transition.  
In the SWAN population, accelerated loss of BMD at the lumbar spine and femoral neck 
was noted between 1 year before FMP to 2 years after. The loss continued in the post-
menopausal era, at a slower rate128. In the same population, lower E2 and greater FSH were 
associated with faster LS BMD loss across menopause. However, these associations varied by 
phase of MT129. In older women (≥ 65 years), E2 <5 pg/ml had 2.5 times greater risk of 
subsequent hip fracture, compared to women with detectable levels130. In the Women’s Health 
Initiative (WHI), women with E2 ≥8 pg/ml had 50% lower risk of hip fractures131. In models 
with SHBG, T and E2 together, high SHBG was an independent risk factor while high 
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bioavailable T was protective. However, the association with E2 was no longer significant. In the 
WHI hormone trial, women on equine estrogen with or without progestin had 30% - 40% 
significantly lower fractures. Despite a slight attenuation in the risk reduction post-intervention, a 
significant hip fracture benefit persisted during the follow up132. Overall there exists strong 
support for the effect of sex hormones on skeletal health.  
4.2 OBESITY 
4.2.1 Muscle and physical function 
In healthy individuals, muscle and bone strength are correlated with body weight. Gravity 
and inertia may increase the production of growth factors through stimulation of 
mechanoreceptors during movement133. Studies have demonstrated that obese individuals have 
low muscle strength and increased risk of disability134. With the slow but continuous increase in 
fat deposition in the muscle, the anti-gravity adaptations may be compromised. Additionally, 
with aging and lack of physical activity, the levels of lipo-protein lipase (LPL) is decreased. This 
could result in increase in intramuscular fat135.  
Reproductive factors are closely related to obesity and body composition. For example, 
early age at menarche (8-11 years) was associated with a 77% greater risk of obesity [OR(95% 
CI) = 1.77(1.30-2.41)]136. Parity was shown to be associated with greater mean BMI [β(95% CI) 
= 0.34(0.29, 0.39)] and  72% higher obesity risk137. The menopausal transition is associated with 
weight gain and greater obesity risk138. Both animal and human studies have shown that early 
bilateral oophorectomy was associated with an increased body fat percentage139. Put together, 
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reproductive factors may affect physical functioning in later life through obesity. It is also 
important to note that the association between low physical functioning and obesity is bi-
directional. It is thus difficult to differentiate the effect and the cause. 
4.2.2 Joint and Osteoarthritis 
Obesity is a major risk factor for the development and progression of OA140. A meta-
analysis of 14 studies reported that for every 5-unit increase in BMI, the risk of hip OA increases 
by 11%140. Holliday et al, reported that life course BMI was associated with 46% greater risk of 
hip OA. In addition, overweight (BMI≥25kg/m2) early in adult life increased the risk of OA, 
independent of age, gender, occupation, social class, smoking, physical activity and metabolic 
diseases141. The increase in the load on the joint, decreased muscle strength and other metabolic 
factors could contribute to an increased risk of OA142. Leptin levels (produced from the adipose 
tissue) parallel that of degenerative enzymes like metalloproteases and nitric oxide143,144, which 
is harmful to the cartilage cells – chondrocytes. Leptin has shown differential effects on 
chrondrocytes between normal and overweight individuals with OA. Lipid 
(hypercholesterolemia) and metabolic (hypertension, metabolic syndrome, low insulin 
sensitivity) factors could also contribute to initiation and progression of OA145.  
Reproductive events may be associated with an increase in body weight and obesity136-
139. Increase in body weight over the life course could contribute to an increased risk of OA in
later life (i.e., mediation effect). 
20 
4.2.3 Bone 
Contrary to the effect on joint and muscle, greater weight is protective of bone loss with 
age146. Increased mechanical loading stimulates differentiation of osteoblasts to increase bone 
formation147. In a meta-analysis (mean age = 63 years), higher BMI was associated with lower 
Bone Mineral Density (BMD) and increased risk of fracture148. Since adipocytes and osteoblasts 
are derived from the same stem cell149, obesity may increase adipogenesis and decrease in bone 
formation150. Adipokines like leptin and adiponectin from fat tissue may play an important role 
in the association between obesity and bone health. In mouse models, greater leptin levels in 
obese individuals also may be detrimental to bone health151. In humans, some studies have 
shown an inverse relationship between adiponectin and BMD152.  However, after accounting for 
adiposity, higher adiponectin and not leptin were associated with greater BMD loss153 and 
fracture risk154. Reproductive factors influence body composition and obesity in later life136-139. 
Thus, it is plausible that the association between reproductive factors and bone health is 
mediated by obesity.  
4.3 INFLAMMATION 
4.3.1 Muscle and Physical function 
Greater levels of inflammatory markers like Insulin like Growth Factor -1 (IGF-1), Interleukin 6 
(IL-6), cystatin-C, and adiponectin have been associated with functional decline in older women, 
independent of age, race and education155. These factors have also been associated with 
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increased risk of disability and mortality in older women156. The association between 
inflammation and functional limitations maybe related to increased protein breakdown in the 
muscle157 and decrease in protein chain synthesis158. This could result in muscle atrophy, and 
lower muscle strength159. 
Reproductive health has been linked to inflammation160-164. Low ovarian function and 
low estrogen levels were associated with greater inflammation160. In a small study (n=25) of 
young Polish women, age at menarche and estradiol were strongly associated with C-Reactive 
Protein (CRP), a non-specific inflammatory marker160. An early age at menarche was also 
associated with a greater cumulative allostatic load over the course of life161. Multiparity maybe 
a precursor to inflammation and obesity162. Breastfeeding has anti-inflammatory benefits in both 
mother and child163. With the menopausal transition, there is an increase in the levels of pro-
inflammatory cytokines like interleukins and Tumor Necrosis Factor-α (TNF-α)164, further 
supporting the protective role of estrogen. Put together, these suggests a possible inflammatory 
pathway between reproductive factors and physical function decline in later life. 
4.3.2 Joint and Osteoarthritis 
Like physical function, an inflammatory pathway to development of OA has been 
suggested. In a subset of patients with OA, the presence of chronic low-grade inflammation 
serves as a precursor for chronic joint disease165. Inflammation of the synovium precedes 
structural changes. In the presence of mechanical stress, proinflammatory markers may be 
produced by the chondrocytes, synovium or by the surrounding tissues. Increase in the 
inflammatory markers and cartilage degrading proteinases could induce death of 
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chondrocytes166. Together with the evidence of reproductive health on inflammation160-164, it is 
plausible that the association between reproductive health and OA is mediated by inflammation. 
4.3.3 Bone 
Skeletal and immune systems are closely related due to shared microenvironment and 
lineages167. IL-6 promotes osteoclast activation and differentiation168. TNF-α has been linked to 
increased bone resorption and osteopenia169. In addition, activation of NO synthesis pathway by 
cytokines, stimulates osteoblast apoptosis170. In addition to the direct protective effect of 
estrogen and androgens on the bone, sex hormones could also down regulate IL-6 expression171. 
Decline in ovarian functioning is also associated with an increase in pro-inflammatory and pro-
osteoclastic cytokines like IL-6, TNF-α and IL-1172. Together with the associations between 
reproductive factors and inflammation160-164, inflammation could mediate the association 
between reproductive factors and poor bone health. 
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5.0  PHYSICAL FUNCTION AND REPRODUCTIVE HEALTH 
Compared to men, women have poorer self-reported health173,174 and perform more 
poorly on physical performance tests than men175,176. Both men and women experience decline in 
physical function over time with accelerated loss with increasing age. Oksuzyan et al, reported 
that while men started with greater grip strength, they experienced a linear decline with age as 
opposed to a non-linear decline (accelerated) in women177. Forrest et al, reported that women lost 
about 2.4% grip strength annually178. Studies have demonstrated a potential hormonal pathway 
leading to accelerated decline in physical function in the post-menopausal era. Samson et al, 
reported that women showed accelerated loss of hand grip strength and knee extensor strength 
after 55 years179. Phillips et al, showed that women in the peri- or post-menopausal state were 
more likely to experience muscle weakness, compared to pre-menopausal women or men180. 
These differences suggest the role of gender specific factors. Both biological and social factors 
have been suggested to explain this difference. Over the life course, women undergo various 
physiological changes to adapt to increasing demands of life. These repeated physiological 
insults could accumulate together and manifest in later life181. Women are also at a greater risk 
for diseases like depression, arthritis and osteoporosis, which could limit physical functioning5. 
In addition, socio-behavioral factors like education, smoking, physical activity could contribute 
to the gender difference in functional decline and disability182. However, the gap persists even 
after accounting for all these factors.  
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Few studies have assessed the effect of reproductive health on functional decline in 
women. The International Mobility in Aging study (aged 65-74 years) reported that early age at 
first birth (≤ 18 years) was associated with 1.75 odds of poorer physical performance (from the 
Short Physical Performance Battery) compared to older mothers. This association was 
independent of age, education, childhood economic adversities and parity183. Similar results were 
reported in midlife Brazilian women (N=473) where women with age at first birth ≤ 18 years 
took 0.5s longer to complete the chair stand test compared to older mothers184. This association 
was independent of age, physical activity, education, menopausal status and hysterectomy. No 
association was noted with grip strength and gait speed. Interestingly, Pirkle et al, did not 
account for the effect of BMI in their study, citing a potential mediatory role of BMI in the 
association between parity and physical function. Despite the potential mediatory role of BMI 
and its change over time, concurrent body weight could significantly influence physical function. 
On the other hand, Camara et al, reported a significant mediation effect of BMI for the 
associations of physical function (chair stand, grip strength and gait speed) with parity and age at 
first birth. Additionally, it is important to note that these results were reported from low 
education and low-income countries. Both factors have been independently associated with poor 
physical function185,186. 
In a study of older Mexican women (≥ 65 years), women with 6 or more pregnancies 
(irrespective of the pregnancy outcomes) performed poorer on the chair rise and walk time tests, 
compared to women with 4 or fewer pregnancies. This association was independent of age, 
nativity, education, severity of incontinency, hysterectomy, and chronic diseases like diabetes, 
arthritis, osteoporosis, stroke and heart failure187. The authors alluded to a potential interplay 
between socioeconomic and biological risk factors that put Mexican Americans at an increased 
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risk of poor physical function in later life. The incomplete uterine involution and cumulative 
stress to the musculature of the pelvic floor could result in subclinical neural damage. With age 
related functional decline, these limitations may become more apparent. Interestingly, like prior 
studies, Aiken et al, failed to account for the effect of body weight on the association between 
pregnancy and physical function in later life. While it could be argued that the change in BMI 
over time, could be in the causal pathway of such an association, it is important to account for 
the effect of current body weight on physical function. 
Tseng et al, reported that, compared to premenopausal women, women with natural or 
surgical menopause were at a 3 folds’ greater risk of substantial functional limitations (defined as 
score of <50 on physical function subscale of Short Form -36 questionnaire), independent of age, 
ethnicity, education, BMI, smoking, diabetes, hypertension, arthritis, depression, and hormone 
use188. This was attributed to a cascade of events (like the Nagi model), including changes in the 
body composition and loss of bone mass which eventually resulted in functional limitation and 
disability. An NHANES (National Health and Nutrition Examination Survey) of older women (≥ 
60 years) reported that age and type of menopause significantly affected physical functioning in 
later life. Women with surgical menopause had 4.4% slower chair rise compared to women with 
natural menopause. Women with later age at menopause (≥ 55 years) had faster walk speed 
compared to early age at menopause (<45 years)189. Sowers et al, reported similar associations 
between surgical menopause and low physical functioning190. Interestingly, the British Birth 
Cohort reported that women with hysterectomy before 40 had significantly lower grip strength 
(5.21 kg lower) compared to hysterectomy after 50 years191. However, the association between 
other reproductive events/factors and level and change in physical function in older women is not 
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clearly understood. Most of these studies were limited by their cross-sectional design and 
relatively small sample sizes.  
 
Figure 5-1: Influence of structural and compensatory reserve on life course trajectory 
 
It was previously believed that over the life course, the functional ability of an individual 
changed over 3 phases – growth, plateau (structural reserve) and then decline42. However, it is 
now believed that there exists an interaction between chronic diseases/risk factors and these 
phases. For example, following exposure to a risk factor or illness, the functioning of a system 
would depend not only on the structural reserve innate to a person, but also on their ability to 
recover from it. This ability has been termed as compensatory reserve48. The compensatory 
reserve changes with age and thus altering the decline in function over time [Figure 3]. In 
addition, these compensatory/adaptive responses may bear an influence on functioning in later 
life. To the best of our knowledge, no studies have assessed the association between reproductive 
factors and changes in physical function over time in older women. Thus, we aim to assess these 
associations cross-sectionally and over time in older women. We hypothesize that reproductive 
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factors and timing of reproductive events shall influence the level of physical functioning in later 
life as well as rate of change of physical function over time. 
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6.0  REPRODUCTIVE HEALTH AND OSTEOARTHRITIS 
Osteoarthritis (OA) is the most common joint disorder accounting for about 3.1 million 
hospitalizations192 and 21.7 million ambulatory physician visits in the country193. In 2003, 9.6% 
men and 18% of women over 60 years had symptomatic OA194 across the world. In the United 
States, 33.6% of those 65 or older suffered from OA195, with nearly 80% reporting functional 
limitations196. Women have 45% greater risk of incident knee and 36% greater risk of hip OA197 
compared to men. 
 
Figure 6-1: Age, sex and site-specific incidence rates of OA 
Age is one of the most important risk factors for OA. The risk of OA increases greatly 
after 50 years197 (around the time of menopausal transition). The risk of hip OA increases 
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continuously with age, reaching peak incidence around 70-79 years198. This increase in risk after 
menopause suggests a potential role of hormones in the development of OA. However, this 
association is unclear. While some observational studies have reported lower odds of OA with 
hormone replacement199, randomized control trials have shown no significant association200.  
The effect of reproductive history on OA risk is poorly understood. Few studies have 
assessed the association between reproductive factors and OA in later life. Lui et al, from the 
Million Women Study assessed the association between age at menarche, parity, and age at 
menopause and the risk of hip or knee replacement. Women who attained menarche ≤ 11years 
had a greater risk of hip (9%) and knee (15%) replacement compared to menarche at age 12. 
Interestingly, the linear trend for inverse association between hip and knee replacements were 
significant. However, later age at menarche (>12 years) showed no significant association. 
Compared to nulliparous women, women with 4 or more children had a greater risk of both hip 
(10%) and knee replacement (46%), with significant linear trends. Current or past use, longer 
duration of HT use and type of hormone (estrogen only or estrogen and progestagen) were 
significantly associated with 13% to 72% increased risk of joint replacement201. These 
associations were independent of age, BMI, alcohol, socioeconomic status(SES), smoking, use of 
oral contraceptive or hormone therapy, parity and age at menarche appropriately201. The authors 
suggested that estrogen exposure may promote osteoarthritic changes resulting in joint 
replacement. No associations or trends were noted with age at menopause. However, it is 
important to note that joint replacement is largely an elective surgery. Socioeconomic status, 
education, diet and physical activity and access to healthcare could be important determinants of 
this association. While OA is the most common cause of joint replacement, the study had limited 
information on knee injury and occupation, which are important risk factors for joint 
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replacement. Additionally, women of low SES in the United States, are less likely to undergo 
joint replacement, possibly due to disparity in access to care202. With the centralized healthcare 
system in the United Kingdom, these results might be less generalizable203. 
Wise et al, demonstrated a direct association between parity and knee OA or replacement. 
Compared to women with 1 child, having 2, 3, or ≥5 children were associated with greater risk of 
knee OA, independent of age, race, education, occupation, or knee injury204. The authors 
attributed these findings to redistribution of weight during pregnancy overloading the knee joint 
and retention of weight following pregnancy may lead to obesity in later life205. It is important to 
note that the study included women with risk factors for knee OA including obesity, knee injury, 
and knee pain or stiffness in the last 30 days. Thus, it is likely that the sample was not 
representative of the general population204. The effect of physical activity was also not accounted 
for.  
Jorgensen et al, reported that greater number of live births were associated with a greater 
risk for OA hospitalization in both men and women. Compared to nulliparous women, women 
with one or more children had a 14% increased risk of hospital diagnosed knee OA, but not hip 
OA. This association was independent of age, marital status, birth cohort, family education, and 
household income206. The authors suggested that the association was possibly due to pregnancy 
related weight gain and retention. However, they could not account for effect of obesity due to 
lack of anthropometric measures from the Danish Population Registers. In addition, use of 
International Classification of Diseases (ICD) codes may allow for potential misclassification.  
Parazzini et al, reported that women (mean age – 53 years) experiencing natural (13%) 
and surgical (18%) menopause were more likely to self-report OA, compared to pre-menopausal 
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women. Women who used HT had 27% were less likely to report OA207. However, these 
associations failed to account for effect of any potential confounders. 
Studies on the effect of HT on osteoarthritis have produced conflicting results. Arden et 
al, suggested that HT may have a protective effect on radiological signs of osteoarthritis208. 
While some studies have supported this hypothesis207, the Women’s Health Initiative showed no 
association between HT and hip or knee replacement209. Multiple studies have demonstrated a 
lack of association between oral contraceptive pill use and osteoarthritis210-213.  
In summary, the association between reproductive factors and osteoarthritis is unclear. 
The research is largely limited to knee OA, with conflicting results. Some studies were also 
limited by self-reported or clinical diagnosis of OA that could lead to potential misclassification 
bias. The peak incidence of hip and knee OA is between 70-79 years, Thus, studies on middle 
aged women may not adequately reflect these associations. To the best of our knowledge, no 
studies have assessed the association between reproductive history and hip OA in older women.  
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7.0  REPRODUCTIVE HEALTH AND BONE GEOMETRY  
The aging process results in loss of structure and composition of the bone leading to 
osteoporosis214. Osteoporosis is a major health problem associated with low impact or 
osteoporotic fractures215. In 1 year, women are more likely to expericence fractures than 
myocardial infarction, coronary death or breast cancer, combined216. Fractures of the hip and 
vertebrae are associated with a significant increase in mortality and disability risk217. Women 
with history of hip fracture had an increased risk of subsequent hip fracture (2.3%/year)218. The 
cost of fractures is estimated to grow from $209 billion to $228 billion between 2006-2015 and 
2016-2025 respectively219. Thus identification of risk factors and its prevention is key.  
The female reproductive system largely influences the growth and development of the 
skeleton. From menarche to menopause, bones undergo constant modelling and remodeling220. 
This process occurs largely through the influence of estrogen on calcium balance and its effects 
on the bone221.  With the menopausal transition, the levels of estrogen decrease resulting in loss 
of bone mineral content leading to osteoporosis and subsequently fractures222. Areal bone 
mineral density (aBMD) is the most commonly used measure to diagnose osteoporosis. 
However, aBMD does not account for bone size and geometry and fails to adequately reflect the 
ethnic/racial differences in fracture rates223. In addition, aBMD is limited by its 2-dimensional 
nature. Therefore, in addition to BMD, accounting for the geometry and structural properties of 
bone can better measure bone strength224. The Hip Structural Analysis (HSA) takes into account 
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bone geometry and predicts femoral neck strength225 and fracture risk226, independent of 
aBMD227. 
Attempts to understand the effect of hip geometry were made as early as 1975 by Phillips 
et al228. In 1984, Martin and Burr used dual energy photon absorptiometry as a non-invasive 
technique to understand the 3-dimensional structure of the bone from a 2 dimensional image229. 
Beck et al, further developed this method and applied them to newer Dual energy Xray 
Absorptiometry (DXA) images230. 
The Hip Structural Analysis (HSA) assesses the hip geometry at 3 anatomical sites on the 
femoral bone – the narrow neck, intertrochanteric region and the shaft. The main principle of the 
HSA is that pixel lines across the axis of the bone reflects the mineral in a cross-section from 
which the geometric properties can be measured231. Geometry is assessed in 5 profiles which are 
1 pixel apart and then averaged at each region. Bone mineral density (BMD) is calculated as the 
average pixels in the region profiles. Cross sectional area (CSA) is assessed as a linear thickness 
(in cm2) cross sectional bone surface divided by the average mineral content of a normal adult 
cortical bone (1.053 g/cm2). Section modulus(SM), an indicator of the bending strength for 
maximum bending stress is computed as cross-sectional moment of inertia (CSMI) divided by 
the maximum distance from the section center to the cortical surface in the image plane (dmax). 
The outer diameter (OD) is the blur-corrected width of the bone. The buckling ratio (BR) is 
measured as a relative thickness of the cortex measured as an estimate of the cortical stability in 
buckling (lower is better). BR is estimated by modelling the cross section as a hollow circular 
annulus of the narrow neck with 60% of the CSA in the cortical shell.  
Some reproductive factors have been studied in association with bone geometry in 
women. In a cross-sectional study of healthy postmenopausal women (N=87, aged 55-79 years), 
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greater parity was associated with significantly lower narrow neck CSA [β (95% CI) = -0.25(-
0.09, -0.01)]. Longer duration of lactation (total lactation period over the life time) was 
associated with greater intertrochanteric BR [0.28(0.04, 0.27)] suggestive of higher fracture risk. 
In addition, longer duration of menopause was associated with greater narrow neck BR [0.24, 
0.01, 0.29)]. These associations were independent of age, and BMI and the other reproductive 
factors232. Interestingly, women with >4 children had lower mean FN and spinal BMD compared 
to women with <2 children232. The association between parity and conventional BMD remains 
controversial. While some early studies suggested an inverse association233, 234 between parity 
and BMD, more recent studies have demonstrated that parity and lactation have little effect on 
BMD or fracture risk235. One potential explanation for the association between parity and low 
BMD in the study could be due to greater BMI in women with greater parity. Lower BMI has 
been shown to be associated with lower BMD236.  
Laskey et al, reported similar association between lactation and hip geometry. In a 
longitudinal study of young women (48 lactating, 23 non-pregnant non-lactating) followed up for 
upto a year, lactating women showed significant decrease in BMD and CSA (narrow neck and 
intertrochanteric) from 2 weeks post-partum to peak lactation independent of weight. Lactating 
women also showed significant increase in BR that was explained by accoutning for weight. 
Interestingly, there was no significnat loss from 2 weeks post partum to post-lactation(>1 year). 
No associations were noted with non-pregnant non-lactating women237. These results are 
consistent with changes in conventional BMD. Lactation is known to be associated with 
temporary loss of FN BMD235,238,239. It has been postulated that the loss of BMD compensates for 
the increased calcium demand during lactation. This is supported by the ineffective apposition of 
the endocortical layers in girls but not boys, during puberty, so as to support pregnancies and 
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lactation112,240. In addition, breast feeding is associated with loss of body weight241. The changes 
in body weight could affect the skeleton through loading effects242, and hence affect 
mineralization. Resumption of menstrual cycles after pregnancy has also been suggested as 
possible driver of bone health recovery after lactation239. 
Similar to changes in aBMD127 and FN strength243, the hip geometry showed accelerated 
change 2 years before the final menstrual period to 1 year after and continued to change in the 
post-menopausal period at a lower rate . We noted a decline in BMD, CSA and Section Modulus 
(SM) and an increase in outer diameter (OD) and buckling ratio (BR). This association was 
independent of body weight, smoking, and physical activity244.  
A large cross-sectinal study (N=1322) of post-menopausal Chinese women (aged 44-87 
years) studied the association between years of menstruation (calculated as time between age at 
menarche to menopause) and hip geometry. They reported that longer years of menstruation and 
higher BMI were significantly associated with greater BMD, CSA and Cortical Thickness (CT) 
and lower OD and BR245. These associations were independet of age, body weight, height, 
eduation, physical activity, smoking status, oral calcium intake and age at menarche. Poor HSA 
measures may be attributed to lower cumulative exposure to estrogen, increased glucocorticoid 
levels, decreased anti-oxidant capacity and physical activity246. 
Few reproductive factors over the life course have been studied in relation to hip 
geometry. Many of these studies were limited by small study populations and cross-sectional 
design or with limited follow up time. Studies were also limited to certain populations, thus 
lacking strength to generalize the results. To the best of our knowledge, the association between 
reproductive factors and HSA levels during midlife has not been previously assessed. With the 
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high social and economic burden of fractures in older women, the association between 
reproductive factors and hip geometry needs to be further explored.  
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8.1 ABSTRACT 
Objective: To assess association between reproductive history with level and rate of change of 
objective measures of physical function (PF) in older women. 
Methods: The Study of Osteoporotic Fractures was a longitudinal study of women, aimed at 
understanding risk factors for fractures. To improve internal validity and reduce survivor bias, 
the analysis was limited to women 65-80 years at baseline with information on reproductive 
factors and 2 or more measures of PF [N=6154, Age, mean(SD)= 70.6(4.1) years, 
BMI=26.5(4.4) kg/m2]. Outcomes were evaluated as both baseline levels and rate of change over 
20 years to complete 5 chair stands, maximum grip strength and 6m gait speed. Linear mixed 
models were used to obtain subject specific rate of change for each PF measure over 20 years. 
Using the population mean and SD of each PF changes, women were classified into maintained, 
expected or accelerated change. Multinomial logistic regression models were then used to assess 
associations with reproductive history. Final models were adjusted for age, education, BMI, 
smoking, alcohol intake, physical activity, diabetes and stroke. 
Results: Women who had later age at menarche [OR (95% CI) = 1.10(1.05, 1.16)], greater parity 
(total live births) [1.07(1.02, 1.12)] and breastfed their offspring [1.22(1.04, 1.42)] were more 
likely to maintain their grip strength. Conversely, women with a history of hysterectomy 
[0.85(0.73, 0.99)] & oophorectomy [0.85(0.73, 0.99)] were associated with accelerated loss of 
grip strength. No associations were noted with other reproductive factors. 
Conclusion: Early life reproductive factors like menarche, parity, and breastfeeding are 
associated with grip strength change in later life. As grip strength is a measure of overall muscle 
strength (or weakness), further understanding of the underlying mechanisms could help design 
targeted interventions to prevent functional decline in later life. 
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8.2 INTRODUCTION 
Preservation of functional status is a key marker of successful aging20. In addition to 
being a precursor of disability247, low physical function is associated with greater mortality 
risk248. Women are more likely to report disability than men5. These differences point to many 
gender-specific biological and social factors that could contribute. For example, women are more 
likely to accumulate greater allostatic load from physiological insults and dysregulation across 
the life course181,183,249. Women are also subject to greater risk of several chronic diseases like 
arthritis, depression and osteoporosis5. In addition, greater predisposition to disability and 
functional decline may be related to socio-behavioral factors like education, smoking, and 
physical activity6,7.  However, these factors account for only a fraction of the gender gap in 
disability6,250. In contrast, the effect of reproductive health on functional decline is poorly 
understood. Some studies have hypothesized that reproductive factors like early childbirth and 
greater parity, may be accountable for greater prevalence of functional limitations and earlier 
decline in physical function183. Early menarche251, greater parity and early childbirth252, 
lactation253 and menopause254, alter the physiologic and metabolic demands of the body. These 
alterations may be more permanent, increasing the risk for chronic diseases12,255-256, thus 
increasing the risk of functional limitations. Few studies have extended support to this theory. In 
a study of middle aged women, parity ≥3 (vs 1-2 children) and first birth <18 years were 
associated with longer time to complete the chair stand test, independent of age, education, 
physical activity and menopausal status184.  In NHANES (mean age ~70 years), natural 
menopause <45 years (vs ≥ 55 years) and surgical menopause were associated with slower gait 
speed and longer chair rise time respectively. These associations were independent of age, race, 
weight and education101. Conversely, young breastfeeding mothers’ (mean age = 27 years) were 
40 
more likely to report better physical functioning, compared to non-breastfeeding mothers, 
independent of age, education, income and parity257. However, these studies were limited by 
cross-sectional design, self-reported physical function measures and/or failure to account for 
significant confounders like body mass index (BMI), physical activity and chronic diseases like 
diabetes. Little is known about these associations in older women. The effect of reproductive 
health on rate of functional decline older women is unknown.  
Maintaining physical function is a key component of successful aging.  With the 
increasing age of the population and the rising healthcare expenditures, there is a critical need to 
understand risk factors for functional decline and to prevent disability in older women. To the 
best of our knowledge, no other study has assessed the effect of reproductive health on the level 
and rate of change of objective measures of physical function later in life. Using the data from 
the Study of Osteoporotic Fractures (SOF), we aimed to assess these associations. We 
hypothesized that reproductive health, characterized by early age at menarche, nulliparity, non-
breastfeeding, oral contraceptive (OC) use , early age at menopause, and history of hysterectomy 
or oophorectomy, would be associated with lower baseline levels as well as greater decline in 
physical functioning in older women. 
8.3 METHODS 
Study population: 
The Study of Osteoporotic Fractures (SOF) is a multi-center longitudinal study of women 
recruited from 4 clinical centers: Baltimore, MD; Monongahela Valley near Pittsburgh, PA; 
Minneapolis, MN; and Portland, OR. SOF was originally designed to understand the risk factors 
41 
for fractures in women258. At baseline (1986-1988), 9704 community dwelling, ambulatory 
women aged 65 years or older were recruited through population based mailings, irrespective of 
osteoporotic status. Women with no history of bilateral hip replacement and ability to walk 
without assistance of another person were eligible to participate. The participants were followed 
with clinical visits and examinations approximately every 2 years for over 20 years (year 20: 
2006-08). The study initially included only Caucasian women (N=9704) due to their higher 
incidence of fracture. African American (AA) women were recruited at year 10 (N=662). The 
study protocol was approved by the Institutional Review Boards at participating institutions and 
informed consent was obtained from all the participants.  
Information on all reproductive factors/events were available for only Caucasian women. 
Hence for the current analyses, the population was limited to Caucasian women aged 65-80 years 
at baseline with 2 or more repeated measures of physical function. Women >80 years were 
excluded to limit survivor bias, improve internal validity and to maximize the follow up 
period259. In addition, outliers from age at menarche (<9 or >16 years) and menopause (<31 or 
>65 years) were excluded from the analyses to limit misclassification bias. The final study 
population consisted of 6154 women (Supplemental figure 8-2).  
Compared to those who were included, the excluded women were older with a lower 
BMI (Age, mean(SD) = 83.37(2.18), BMI=25.46(3.65)). The excluded population had poorer 
physical functioning at baseline with longer time to complete the chair stand test (mean(SD) = 
15.75(6.89) s), lower grip strength (18.96(3.85) kg), and slower gait speed (0.84(0.22) m/s). The 
age at menarche and menopause for all included and excluded ranged between 8-26 and 14-68 
years respectively.  
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Study measures: 
Physical function:  
For the current study 3 objective measures of physical function were included - chair 
stands, grip strength, and gait speed260. Chair stand was measured as the number of seconds 
required to stand from a straight-back chair, 5 times, without using arms. Women who were 
unable to complete the chair stand test received an arbitrary value of 70 seconds was assigned (5 
seconds greater than the highest value), to allow categorization of these women in the lowest 
quartile/accelerated loss group.  Grip strength was measured from both hands, in standing 
position using a handheld isometric dynamometer (Preston Grip dynamometer, Takei Kiki 
Kogyo, Japan). Maximum grip strength recorded from right or left hand (in kilograms(kg)) was 
used for current analyses261. Gait speed (meters/second) was measured as the number of seconds 
needed to walk 6 meters, while walking at usual pace. 
Reproductive factors: 
The SOF study obtained information on multiple reproductive factors from 
questionnaires. Age at menarche and menopause were assessed as age at first and last menstrual 
periods respectively. Parity was reported as the total number of live births. Breast feeding 
(yes/no) was defined as having breastfed one or more children.  Use of OCPs (yes/no) was self-
reported as ever use of birth control pills. Hysterectomy and oophorectomy were self-reported as 
surgical removal of uterus and one or more ovaries respectively. All reproductive data except age 
at menarche (visit 2) were collected at baseline. Age at menarche, parity, and age at menopause 
were assessed as both continuous and categorical variables. Age at menarche was categorized 
into 4 groups – 9-10, 11-12, 13-14, 15-16 years. Similarly, age at menopause was categorized 
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into 5 groups - ≤40, 41-45, 46-50, 51-55 and >55 years. Parity was classified into 3 groups – 
nulliparous, 1-3 and >3 children. 
Other measurements: 
Other factors included in the analyses were collected at baseline. Demographic factors 
like age (years), and education (total number of years of education obtained) were obtained from 
questionnaires. BMI (kg/m2) was calculated as weight in kilograms divided by height squared in 
meters. Smoking and alcohol consumption were self-reported. Smoking status was assessed as 
ever or never smoker. Alcohol intake was reported as total number of drinks per day in the last 
30 days. Physical activity was assessed using a modified Harvard alumni questionnaire262. 
Women reported the distance and frequency they walked each day in city blocks or its 
equivalent. They also reported duration of activities like swimming, dancing, gardening, aerobics 
etc. in the last year. The physical activity was then calculated as a weighted estimate of total 
kilocalorie expenditure per week over the past year263.  Physician diagnoses of diabetes and 
stroke was self-reported by the participants.  
Statistical analyses: 
Pearson coefficients were used to estimate correlations among the reproductive factors. 
Baseline characteristics were summarized as mean (SD) for continuous measures and 
frequencies (percentages) for categorical variables.   
At baseline, associations between the reproductive factors and physical function were 
assessed using linear regression models. Women with history of hysterectomy were excluded in 
models assessing age at menopause since the latter could not be accurately estimated. In 
addition, nulliparous women were excluded from breastfeeding analyses. 
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To assess change over time, multiple approaches were used. Locally Weighted 
Scatterplot Smoothing (LOESS) regression models were used to examine the trajectories of 
physical function over time.  From this, linear trajectories (increase in chair stand time and 
decline in grip strength and gait speed) were noted.  
Next, we tested whether the population-average trajectory of each physical function 
measure overtime can be separated into distinct trajectories (e.g. not all study population follow 
the same trajectory of change in each physical function measure) using group based trajectory 
modeling264. Grip strength and gait speed showed similar group trajectories thus lacking 
evidence to demonstrate the existence of distinct trajectories of these physical function measures 
over time. Three distinct trajectory groups of time needed to complete chair stand test were 
identified [Supplemental figure 8-3]. Group 1 (N (%)= 4672 (83.6%)) maintained their chair 
stand for the duration of follow up. Group 2 women (579(12.2%)) maintained the chair stand 
time up until year 10, with steep increase in chair stand time thereafter. Group 3 (223(4.2%)) 
demonstrated a gradual increase in chair stand till year 4, followed by a steep increase in chair 
stand thereafter. Using multinomial logistic regression, we estimated the odds of belonging to the 
3 groups with group 2 as our referent. 
To further characterize our findings, we used linear mixed model analyses. Subject-
specific slopes and intercepts for each physical function measure were estimated using random 
effects models. Repeated measures of each physical function assessments were modeled 
separately as a function of time. Fixed effect parameter of time since baseline provides an 
estimate of the population-average change in each physical function measure per year, while the 
random effect of time since baseline provides estimates of subject-specific deviation from the 
population-average. Using the estimated subject-specific slopes of change in physical function 
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per year, women were then categorized into “maintained”, “expected” and “accelerated” physical 
function change overtime. As chair stand time increases with age265, women were considered to 
have maintained if their chair stand slope was ≤ mean, expected if the slope was within 1SD 
above the mean and accelerated if the slope was greater than 1 SD above the mean. Grip strength 
and gait speed decrease over time155, thus women were considered as maintained if their 
respective slopes were ≥mean, expected if the slopes were within 1SD below the mean, and 
accelerated if the slopes were greater than 1SD below the mean. We used multinomial logistic 
regression to estimate the odds of having maintained or accelerated change in physical function 
with the expected group forming the referent group (figure 8-1). For chair stand test, the results 
from the mixed effect models were similar to those from group based trajectory modelling. Only 
results from the linear mixed models are presented below. Both cross-sectional and longitudinal 
analyses were conducted univariately and then adjusted for all the potential confounders. 
8.4 RESULTS 
Using Pearson correlation coefficients, we noted small but significant correlations 
between the reproductive factors (p<0.05) [Supplemental table 8-6]. Strong correlations included 
parity and breastfeeding (r=0.17) and hysterectomy and oophorectomy (r=0.79). The baseline 
characteristics of the population are summarized in Table 8-1.  
Baseline analyses – Univariately [Table 8-2], later age at menopause was associated with 
faster chair stand time. Menopause ≤40 years showed slower chair stand time compared to 
referent population [menopause 51-55 years]. Oophorectomy was associated with longer 0.3s 
longer chair stand time. These associations were no longer significant after adjusting for 
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confounders. In the fully adjusted model, menarche between 11-12 years was significantly 
associated with faster chair stand time compared to the referent population [menarche 13-14 
years]. The reverse confounding effect was explained by age, BMI, smoking, diabetes and 
stroke. 
In the fully adjusted models, Later age at menarche was associated with greater grip 
strength. Menarche between 11-12 years had significantly lower grip strength compared to 
referent population [menarche 13-14 years]. Parity 1-3 and ≥4 were associated with greater grip 
strength, compared to nulliparity. No significant associations were noted with the other menarche 
categories. Hysterectomy and oophorectomy were associated with lower grip strength. 
Menopause between 41-45 years was associated with greater grip strength compared to 
menopause between 51-55 years only in the final model. This suppressor effect was attributable 
to age and diabetes.  
Univariately, breastfeeding, and hysterectomy were associated with slower gait speed 
while OC use and later age at menopause were associated with faster gait speeds. However, these 
associations were explained by adjusting for potential confounders. 
Longitudinal analyses - Mean slope for chair time, grip strength and gait speed were 
0.47s/year, -0.35kg/year and -0.02m/s/year respectively. The mean slope in the accelerated group 
was +2.19s/year (n=535), -0.38kg/year (n=915) and -0.03m/s/year (n=825) for chair stand, grip 
strength and gait speed respectively [Figure 8-1]. 
Univariately, later age at menopause were 3% less likely to have accelerated chair stand 
increase relative to expected increase. This association was largely explained by age, diabetes, 
and stroke. No significant associations were noted with other reproductive factors. 
In the final models, women with later age at menarche (10%), or greater parity (7%) were 
47 
more likely to have maintained grip strength relative to expected group [Table 8-4].  Compared 
to nulliparous, women with 1-3 (91%) or >3 (115%) children were more likely to have 
maintained grip strength compared to expected group. Women with hysterectomy or 
oophorectomy were 15% less likely to have maintained grip strength. Women with 
oophorectomy [1.28(1.03, 1.58)] had 28% greater risk of accelerated loss of grip strength, 
compared to expected loss. No significant associations were noted with the other reproductive 
factors. 
Univariately, women with greater parity (8%), and OC use (31%) had a greater likelihood 
of maintaining gait speed compared to expected loss [Table 8-5]. Compared to nulliparous 
women, women with >3 children were 50% more likely to maintain their gait speed relative to 
expected loss.  Women with hysterectomy (13%) were less likely to have maintained gait speed. 
However, these associations did not remain significant in the fully adjusted models. No 
associations were noted with age at menarche, parity, breast feeding, age at menopause or 
oophorectomy.  
No associations were noted with use or length of hormone therapy with any of our 
outcomes (results not shown).   
8.5 DISCUSSION 
We found selective reproductive factors may influence both the level and rate of change 
in grip strength in older women. At baseline, later age at menarche, and greater parity were 
associated with higher grip strength. Conversely, a history of hysterectomy or oophorectomy was 
associated with lower levels of grip strength. Longitudinally, women with a later age at 
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menarche, greater parity, and history of breastfeeding were more likely to maintain their grip 
strength while women who had hysterectomy or oophorectomy were less likely to maintain their 
grip strength, while a history of an oophorectomy was associated with a greater likelihood of 
accelerated loss of grip strength. These associations were independent of age, BMI, education, 
physical activity, smoking, diabetes and stroke. Our results support a life course perspective and 
highlights the association of multiple reproductive factors across life with grip strength in later 
life. 
Gait speed266, chair stand266 and grip strength267 have been linked to adverse health and 
mortality in later life. However, they reflect different physiologic processes. Successful 
completion of the chair stand reflects strength268,269 of the proximal muscles, neuromuscular 
control as well as coordination and integration of cardiovascular and respiratory systems191,270. 
Walking entails muscle strength101 as well as coordination190. Although grip strength is a simple 
isometric measure of upper body muscle strength191, it is a known surrogate marker for various 
chronic diseases including cardiovascular disease and sarcopenia271,272. In addition, grip strength 
acts as a proxy for overall muscle strength273 and is a predictor of functional limitation and 
disability274,275. Grip strength is also significantly correlated with arm, back, leg276-278 and 
respiratory muscle strength279. 
Our study found significant results only with grip strength. We believe complex 
hormonal and biomechanical factors may mediate these associations. Early menarche, and other 
indicators of early biological maturity, is associated with greater adult BMI280. 
Obesity/overweight in early, middle or late adulthood has been linked to mobility limitations in 
old age281.Thus, later age at menarche may indicate leaner, healthier population, retaining 
functional abilities in later life. On the other hand, greater parity282 is associated with greater 
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body weight while breastfeeding is associated with postpartum weight loss283. This association 
differs by number of births, race and maternal BMI282. Interestingly, arm muscle area, an 
indicator of muscle mass, also increases in late pregnancy284. Coupled with an active lifestyle 
with young children, the increase in muscle mass could reflect as greater muscle strength in later 
life. Studies have also reported increase in BMI following hysterectomy/oophorectomy285, 
increasing risk of functional limitations in later life. On the other hand, 
hysterectomy/oophorectomy may also be manifestations of underlying poor health. 
In addition, the exposure to levels of hormones particularly estrogen, progesterone and 
testosterone vary across life. While the effect of sex-steroid hormones on muscle function 
remains unclear, studies have shown that these hormones may act independently105 or along with 
other hormones286 to affect physical functioning. Estrogen increases rapidly around menarche251, 
and decreases around menopause254. Pregnancy is associated with increased levels of both 
estrogen and progesterone. High levels of progesterone can alter the effect of estrogen in the 
body110 by blocking estrogen receptors111. Therefore, the effect of higher cumulative exposure to 
estrogen with greater parity, may be altered through high levels of progesterone. Together, these 
factors could be associated with greater grip strength. In addition, breast feeding reduces the 
synthesis of estrogen112 and progesterone113 while increasing the levels of follicle stimulating 
hormone111. These changes in hormones could have lasting effects on muscle structure and 
function. However, to completely understand the effect of hormones on physical function, 
repeated longitudinal assessment of hormones, especially in later life, is required. A life-course 
approach, by definition, aims to understand the long-term effects of biological and psycho-social 
processes from gestation to adult life58. However, accurately assessing these biological and 
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psycho-social influences over time can be challenging given requirements for detailed and 
comprehensive assessments over long period of follow up. 
However, few studies have assessed the association between reproductive health and 
physical function levels in later life257. The results of our study are largely consistent with 
existing literature on reproductive health and physical function in early life183,191,257. In the recent 
years, there has been increasing research supporting the relationship between early life 
reproductive factors and later life health. Early age at menarche and menopause have been linked 
to increased risk of mortality287 while later age at menarche, childbearing, breastfeeding, OC use 
have been related to decreased risk of all-cause mortality, lower circulatory and heart diseases288. 
Parity289 and menopause290 were inversely related to hip fractures. The findings from our study 
are consistent with these findings and extend the association to changes in grip strength in later 
life. 
The strengths of our study include the large community population who were followed 
over 20 years. SOF collected information on multiple reproductive factors as well as objective 
assessments of multiple physical functions over time allowing for both cross-sectional and 
longitudinal analyses. However, the study has its limitations. Reproductive data was available 
only for Caucasian women. Thus, our results may not be generalizable to women of other 
race/ethnicities. Use of retrospective reports of reproductive health may be subject to recall bias. 
Since the women were 65 and older in 1986-88, there were few women who reported prior OC 
use; thus, limiting statistical power. Simultaneous comparisons of the many reproductive factors 
may also induce a problem of multiplicity/multiple comparisons i.e., statistical significance is 
likely due to chance. However, the consistent results in the cross-sectional and longitudinal 
analyses provides some validity. We were also unable to assess the effect of hormone levels in 
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later life on physical function. Despite these limitations, to the best of our knowledge, no studies 
have assessed the association between multiple reproductive factors and the level and rate of 
change of objective measures of physical function in later life.  
8.6 CONCLUSION 
Our study demonstrated possible influence of reproductive factors over the life course on 
grip strength in later life both cross-sectionally and over time. While later age at menarche and 
greater parity had protective effects, hysterectomy and oophorectomy may be associated with 
poorer grip strength in later life. These associations were independent of potential confounders 
and may be mediated through complex biomechanical, and hormonal pathways. Further studies 
are required to understand these pathways and provide appropriate interventional support to 
prevent functional decline and disability in older women. 
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8.7 TABLES AND FIGURES 
Table 8-1: Population characteristics 
All women 
(N=6154) 
Menarche 9-10 
(n=134) 
Nulliparity (n=168) Menopause <40 
(n=289) 
Hysterectomy 
(n=1666) 
Oophorectomy 
(n=1595) 
Age (years) 70.56(4.05) 70.70(4.11) 71.10(3.95) 71.35(4.21) 70.66(4.08) 70.42(3.99) 
Education (years) 12.73(2.72) 13.23(2.64) 13.06(2.92) 12.33(2.65) 12.53(2.71) 12.50(2.69) 
BMI (kg/m2) 26.46(4.43) 27.16(4.49) 25.90(4.31) 26.33(4.49) 26.73(4.51) 26.68(4.58) 
Ever smoker N(%)         2503(40.82) 64(47.76) 102(60.71) 128(44.44) 662(39.81) 661(41.52) 
Alcohol consumption (total 
drinks/day)  1.01(0.84) 1.07(0.79) 1.21(0.85) 1.12(0.80) 1.02(0.78) 1.04(0.78) 
Physical activity (kcal/week) 1521.59(1655.07) 2073.56(2985.82) 1649.82(1762.29) 1348.42(1405.81) 1509.19(1615.15) 1533.63(1677.38) 
Diabetes N(%) 406(6.61) 15(11.19) 16(9.58) 25(8.71) 127(7.64) 115(7.22) 
Stroke N(%) 161(2.63) 7(5.34) 5(3.03) 7(2.44) 58(3.50) 51(3.21) 
Age at menarche (years) 12.98(1.36) 9.79(0.41) 12.88(1.49) 12.99(1.43) 12.91(1.34) 12.93(1.36) 
Menarche (years) N(%) 
         9-10 
        11-12 
        13-14 
        15-16 
134(2.18) 
2180(35.42) 
3034(49.30) 
806(13.10) 
N/A 
8(4.76) 
62(36.90) 
73(43.45) 
25(14.88) 
14(4.84) 
87(30.10) 
149(51.56) 
39(13.49) 
32(1.92) 
649(38.96) 
778(46.70) 
207(12.42) 
34(2.13) 
602(37.74) 
761(47.71) 
198(12.41) 
Parity 2.68(1.51) 2.60(1.58) N/A 2.23(1.46) 2.60(1.45) 2.46(1.43) 
Parity N(%) 
         Nulliparous 
         <=3 
>3
168(3.23) 
3805(73.14) 
1229(23.63) 
8(6.96) 
79(68.70) 
28(24.35) 
N/A 
16(7.48) 
163(76.17) 
35(16.36) 
54(3.76) 
1073(74.77) 
308(21.46) 
70(5.23) 
1014(75.73) 
255(19.04) 
Breast fed N(%)* 3551(70.36) 72(67.29) N/A 131(66.16) 980(70.76) 880(69.18) 
Oral contraceptive user N(%) 291(4.74) 9(6.72) 2(1.19) 3(1.04) 71(4.27) 71(4.46) 
Age at menopause (years) 48.94(4.78) 48.17(6.01) 48.75(6.19) 38.32(2.22) N/A 47.77(5.56) 
Menopause (years) N(%) 
        <=40  
        41-45 
        46-50 
        51-55 
>55
289(6.44) 
797(17.76) 
1782(39.71) 
1401(31.22) 
219(4.88) 
14(13.73) 
18(17.65) 
31(30.39) 
32(31.37) 
7(6.86) 
16(14.04) 
16(14.04) 
36(31.58) 
36(31.58) 
10(8.77) 
N/A N/A 
31(12.06) 
49(19.07) 
97(37.74) 
72(28.02) 
8(3.11) 
Hysterectomy N(%) 1666(27.08) 32(23.88) 54(32.14) 0(0) N/A 1338(83.94) 
Oophorectomy N(%) 1595(26.34) 34(25.56) 70(42.68) 31(10.76) 1338(84.63) N/A 
Chair Stand Time time(sec) 12.12(4.71) 12.46(4.49) 12.49(4.51) 12.83(4.30) 12.20(4.28) 12.23(4.33) 
Maximum grip strength (kg) 22.61(4.30) 22.31(4.44) 21.81(4.25) 22.31(4.69) 22.23(4.32) 22.33(4.33) 
Gait speed (m/s) 1.04(0.21) 1.04(0.26) 1.05(0.21) 0.99(0.21) 1.03(0.21) 1.03(0.22) 
*excluding nulliparous women
53 
 
 
Table 8-2: Cross-sectional association between Reproductive factors and Physical function at baseline 
 Chair Stand Time Grip strength Walk speed 
 Unadjusted model 
[β (95% CI)] 
Multivariate model 
[β (95% CI)] 
Unadjusted model 
[β (95% CI)] 
Multivariate model 
[β (95% CI)] 
Unadjusted model 
[β (95% CI)] 
Multivariate model 
[β (95% CI)] 
Age at menarche (cont.) -0.002(-0.09, 0.08) 0.003(-0.09, 0.09) 0.09(0.01, 0.17) 0.17(0.07, 0.26) 0.001(-0.003, 0.01) 0.002(-0.002, 0.01) 
Age at menarche  
         9-10 
        11-12  
        13-14 [Ref] 
        15-16 
 
0.28(-0.54, 1.10) 
-0.18(-0.44, 0.08) 
Ref 
-0.06(-0.42, 0.31) 
 
0.17(-0.69, 1.02) 
-0.29(-0.54, -0.03) 
Ref 
-0.17(-0.53, 0.20) 
 
-0.37(-1.11, 0.38) 
-0.22(-0.46, 0.02) 
Ref 
0.12(-0.22, 0.45) 
 
-0.61(-1.50, 0.28) 
-0.31(-0.58, -0.04) 
Ref 
0.20(-0.18, 0.59) 
 
-0.0004(-0.04, 0.04) 
-0.01(-0.02, 0.005) 
Ref 
-0.001(-0.02, 0.01) 
 
0.003(-0.04, 0.04) 
-0.002(-0.01, 0.01) 
Ref 
0.01(-0.004, 0.03) 
Parity (cont.) -0.02(-0.11, 0.06) 0.02(-0.07, 0.10) 0.19(0.11, 0.27) 0.14(0.05, 0.23) -0.001(-0.01, 0.003) -0.003(-0.007, 0.001) 
Parity a 
        Nulliparous 
        1-3 
        >3 
 
Ref 
-0.51(-1.20, 0.18) 
-0.44(-1.16, 0.28) 
 
Ref 
-0.12(-0.80, 0.56) 
-0.01(-0.73, 0.70) 
 
Ref 
0.75(0.08, 1.42) 
1.29(0.59, 1.99) 
 
Ref 
1.00(0.28, 1.73) 
1.23(0.47, 1.99) 
 
Ref 
-0.01(-0.04, 0.02) 
-0.01(-0.05, 0.02) 
 
Ref 
-0.01(-0.04, 0.02) 
-0.02(-0.05, 0.02) 
Breast fed b   -0.09(-0.36, 0.17) -0.26(-0.54, 0.01) 0.08(-0.18, 0.34) 0.20(-0.10, 0.49) -0.02(-0.03, -0.003) -0.002(-0.02, 0.01) 
Oral Contraceptive Pill 
use c 
-0.55(-1.11, 0.003) 0.49(-0.03, 1.02) 0.79(0.28, 1.30) -0.22(-0.77, 0.33) 0.05(0.03, 0.08) -0.01(-0.04, 0.01) 
Age at menopause (cont.) -0.03(-0.06, -0.01) -0.01(-0.04, 0.02) 0.02(-0.004, 0.05) -0.02(-0.05, 0.01) 0.003(0.002,0.004) 0.001(-0.003, 0.002) 
Menopause (years)  
        ≤40  
        41-45 
        46-50 
        51-55 [Ref] 
        >55 
 
0.80(0.22, 1.39) 
0.09(-0.31, 0.49) 
-0.07(-0.40, 0.25) 
Ref 
-0.38(-1.04, 0.27) 
 
0.38(-0.24, 0.99) 
-0.08(-0.50, 0.34) 
-0.25(-0.59, 0.09) 
Ref 
-0.21(-0.90, 0.48) 
 
-0.48(-1.02, 0.06) 
0.01(-0.36, 0.38) 
-0.08(-0.38, 0.22) 
Ref 
0.46(-0.16, 1.07) 
 
0.10(-0.53, 0.72) 
0.51(0.08, 0.93) 
0.29(-0.05, 0.63) 
Ref 
0.45(-0.25, 1.15) 
 
-0.06(-0.09, -0.04) 
-0.02(-0.04, -0.003) 
-0.01(-0.02, 0.01) 
Ref 
0.01(-0.02, 0.04) 
 
-0.02(-0.05, 0.01) 
-0.005(-0.01, 0.02) 
0.005(-0.01, 0.02) 
Ref 
-0.003(-0.04, 0.03) 
Hysterectomy e 0.25(-0.01, 0.52) 0.09(-0.17, 0.36) -0.52(-0.76, -0.28) -0.44(-0.71, -0.16) -0.02(-0.03, -0.003) -0.002(-0.01, 0.01) 
Oophorectomy f 0.34(0.07, 0.61) 0.14(-0.13, 0.41) -0.40(-0.65, -0.16) -0.40(-0.68, -0.11) -0.01(-0.02, 0.003) 0.001(-0.01, 0.01) 
 
Reproductive factors were modelled independently and then adjusted for confounders; *adjusted for age at menarche; a Ref - >3; b Excluding nulliparous women, Ref – never 
breastfed; c Ref – No Oral contraceptive use; d Ref- no HRT; e Ref- no hysterectomy; f Ref-no oophorectomy  
Multivariate model – adjusted for age, BMI, education, smoking, alcohol consumption, physical activity, diabetes and stroke 
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Figure 8-1: Mean slope of physical function change by category 
Using subject specific linear mixed models, change in the physical function over time was assessed.  Based on the mean and SD of change, women were 
categorized into 3 groups - maintained, expected and accelerated change. As chair stand (s) increases with time, +1SD change was used. For grip strength (kg) and 
gait speed (m/s) -1SD was used as they decrease over time. 
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Table 8-3: Association between reproductive factors and rate of change of chair stand time 
 Chair Stand Time 
 Unadjusted model 
[OR(95%CI) 
 Multivariate model 
[OR (95% CI)] 
 Maintained Accelerated Expected Maintained Accelerated 
Age at menarche (cont.) 0.97(0.93, 1.01) 0.99(0.92, 1.07) Ref 0.95(0.90, 1.00) 0.99(0.90, 1.09) 
Age at menarche 
9-10 
11-12 
13-14 [Ref] 
15-16 
 
0.77(0.52, 1.15) 
1.13(0.99, 1.30) 
Ref 
0.95(0.79, 1.14) 
 
1.05(0.56, 1.97) 
1.09(0.87, 1.36) 
Ref 
1.20(0.89, 1.36) 
Ref  
1.18(0.67, 2.08) 
1.17(0.99, 1.40) 
Ref 
0.99(0.78, 1.25) 
 
1.56(0.68, 3.59) 
0.99(0.74, 1.32) 
Ref 
1.22(0.84, 1.76) 
Parity (cont.) 1.02(0.97, 1.06) 0.99(0.92, 1.07) Ref 0.99(0.94, 1.05) 1.00(0.91, 1.10) 
Parity a 
Nulliparous 
1-3 
>3 
 
Ref 
1.24(0.86, 1.78) 
1.21(0.83, 1.77) 
 
Ref 
0.90(0.51, 1.58) 
0.81(0.45, 1.48) 
Ref  
Ref 
1.34(0.88, 2.03) 
1.12(0.72, 1.74) 
 
Ref 
1.26(0.61, 2.59) 
1.11(0.51, 2.39) 
Breast fed b 0.90(0.78, 1.04) 0.92(0.72, 1.18) Ref 0.94(0.78, 1.13) 0.82(0.60, 1.11) 
Oral Contraceptive Pill use c 1.24(0.92, 1.68) 1.11(0.68, 1.81) Ref 0.80(0.56, 1.14) 1.65(0.95, 2.88) 
Age at menopause (cont.) 1.01(0.99, 1.03) 0.97(0.95, 0.99) Ref 0.99(0.98, 1.02) 0.98(0.95, 1.01) 
Menopause (years) 
<=40 
41-45 
46-50 
51-55 [Ref] 
>55 
 
0.79(0.59, 1.08) 
0.88(0.72, 1.09) 
0.94(0.79, 1.12) 
Ref 
1.11(0.78, 1.59) 
 
1.58(0.99,2.49) 
1.19(0.84, 1.68) 
0.94(0.79, 1.12) 
Ref 
1.02(0.54, 1.90) 
Ref  
0.95(0.65, 1.39) 
1.06(0.81, 1.38) 
1.07(0.87, 1.33) 
Ref 
1.06(0.68, 1.65) 
 
1.14(0.62, 2.09) 
1.23(0.80, 1.91) 
1.12(0.78, 1.61) 
Ref 
0.72(0.30, 1.72) 
Hysterectomy e 0.90(0.79, 1.03) 0.99(0.80, 1.24) Ref 0.90(0.76, 1.07) 0.90(0.68, 1.20) 
Oophorectomy f 0.92(0.80, 1.05) 0.99(0.80, 1.25) Ref 0.90(0.76, 1.07) 0.88(0.65, 1.18) 
 
Reproductive factors were modelled independently and then adjusted for confounders; *adjusted for age at menarche; a 
Ref - >3; b Excluding nulliparous women, Ref – never breastfed; c Ref – No Oral contraceptive use; d Ref- no HRT; e Ref- 
no hysterectomy; f Ref-no oophorectomy  
Multivariate model – adjusted for age, BMI, education, smoking, alcohol consumption, physical activity, diabetes and 
stroke  
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Table 8-4: Association between reproductive factors and rate of change in grip strength 
 Grip Strength 
 Unadjusted model 
[OR(95%CI) 
 Multivariate model 
[OR (95% CI)] 
 Maintained Accelerated Expected Maintained Accelerated 
Age at menarche (cont.) 1.07(1.03, 1.12) 0.97(0.92, 1.03) Ref 1.10(1.05, 1.16) 0.95(0.88, 1.02) 
Age at menarche  
         9-10 
        11-12  
        13-14 [Ref] 
        15-16 
  
0.71(0.48, 1.04) 
0.84(0.74, 0.95) 
Ref 
1.06(0.89, 1.25) 
  
1.01(0.86, 1.20) 
0.87(0.68, 1.12) 
Ref 
0.87(0.68, 1.12) 
Ref 
  
0.67(0.41, 1.08) 
0.80(0.69, 0.92) 
Ref 
1.05(0.85, 1.30) 
  
0.81(0.40, 1.65) 
1.08(0.88, 1.33) 
Ref 
0.80(0.58, 1.10) 
Parity (cont.) 1.08(1.04, 1.13) 0.95(0.89, 1.01) Ref 1.07(1.02, 1.12) 0.95(0.88, 1.03) 
Parity a 
        Nulliparous 
        1-3 
        >3 
  
Ref 
1.78(1.26, 2.51) 
2.15(1.50, 3.08) 
  
Ref 
1.04(0.68, 1.60) 
0.91(0.57, 1.44) 
Ref 
  
Ref 
1.91(1.28, 2.85) 
2.15(1.41, 3.27) 
  
Ref 
1.15(0.69, 1.92) 
1.05(0.61, 1.84) 
Breast fed b   1.10(0.97, 1.26) 0.95(0.79, 1.14) Ref 1.14(0.97, 1.34) 0.79(0.63, 1.00) 
Oral Contraceptive Pill use c 1.22(0.94, 1.57) 0.51(0.32, 0.82) Ref 0.84(0.62, 1.12) 0.73(0.43, 1.24) 
Age at menopause (cont.) 1.01(0.99, 1.02) 0.98(0.97, 1.00) Ref 0.99(0.98, 1.01) 0.98(0.96, 1.00) 
Menopause (years)  
        <=40  
        41-45 
        46-50 
        51-55 [Ref] 
        >55 
  
0.79(0.60, 1.05) 
0.94(0.78, 1.14) 
0.99(0.85, 1.15) 
Ref 
1.13(0.83, 1.55) 
  
1.32(0.91, 1.91) 
0.96(0.73, 1.28) 
1.09(0.87, 1.36) 
Ref 
0.75(0.45, 1.26) 
Ref 
  
0.96(0.68, 1.35) 
1.13(0.89, 1.42) 
1.15(0.95, 1.38) 
Ref 
1.10(0.76, 1.60) 
  
1.24(0.78, 1/95) 
0.96(0.68, 1.36) 
1.03(0.78, 1.36) 
Ref 
0.60(0.30, 1.19) 
Hysterectomy e 0.87(0.77, 0.98) 1.24(1.05, 1.47) Ref 0.85(0.73, 0.99) 1.22(0.99, 1.51) 
Oophorectomy f 0.89(0.79, 1.01) 1.20(1.01, 1.43) Ref 0.85(0.73, 0.99) 1.28(1.03, 1.58) 
 
Reproductive factors were modelled independently and then adjusted for confounders; *adjusted for age at menarche; a 
Ref - >3; b Excluding nulliparous women, Ref – never breastfed; c Ref – No Oral contraceptive use; d Ref- no HRT; e Ref- 
no hysterectomy; f Ref-no oophorectomy  
Multivariate model – adjusted for age, BMI, education, smoking, alcohol consumption, physical activity, diabetes and 
stroke 
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Table 8-5: Association between reproductive factors and rate of change in walk speed 
                          Walk speed  
 Unadjusted model 
[OR(95%CI) 
 Multivariate model 
[OR (95% CI)] 
 Maintained Accelerated Expected Maintained Accelerated 
Age at menarche (cont.) 1.01(0.97, 1.05) 0.94(0.89, 1.00) Ref 1.01(0.96, 1.06) 0.96(0.90, 1.04) 
Age at menarche  
         9-10 
        11-12  
        13-14 [Ref] 
        15-16 
 
0.80(0.55, 1.17) 
0.91(0.81, 1.03) 
Ref 
0.87(0.74, 1.03) 
 
0.97(0.57, 1.66) 
1.07(0.90, 1.27) 
Ref 
0.80(0.62, 1.04) 
Ref  
1.08(0.67, 1.74) 
0.91(0.78, 1.05) 
Ref 
0.85(0.69, 1.04) 
 
0.67(0.30, 1.48) 
1.05(0.85, 1.30) 
Ref 
0.85(0.69, 1.04) 
Parity (cont.) 1.08(1.03, 1.12) 1.01(0.95, 1.07) Ref 1.05(0.99, 1.01) 0.98(0.91, 1.06) 
Parity a 
        Nulliparous 
        1-3 
        >3 
 
Ref 
1.20(0.85, 1.69) 
1.50(1.05, 2.15) 
 
Ref 
0.68(0.45, 1.05) 
0.71(0.45, 1.13) 
Ref  
Ref 
1.23(0.82, 1.84) 
1.40(0.92, 2.15) 
 
Ref 
0.72(0.44, 1.18) 
0.69(0.40, 1.18) 
Breast fed b   0.98(0.86, 1.12) 1.25(1.02, 1.53) Ref 1.04(0.89, 1.22) 1.15(0.90, 1.47) 
Oral Contraceptive Pill use c 1.31(1.10, 1.70) 1.14(0.77, 1.67) Ref 0.91(0.67, 1.23) 1.15(0.73, 1.81) 
Age at menopause (cont.) 1.01(0.99, 1.02) 0.99(0.98, 1.02) Ref 0.99(0.97, 1.01) 0.98(0.96, 1.00) 
Menopause (years)  
        <=40  
        41-45 
        46-50 
        51-55 [Ref] 
        >55 
 
0.94(0.71, 1.23) 
0.88(0.73, 1.07) 
0.83(0.71, 0.97) 
Ref 
0.86(0.63, 1.17) 
 
0.94(0.63, 1.42) 
1.01(0.77, 1.33) 
0.89(0.71, 1.12) 
Ref 
0.94(0.60, 1.48) 
Ref  
1.21(0.86, 1.71) 
1.05(0.83, 1.33) 
0.95(0.79, 1.14) 
Ref 
0.81(0.55, 1.18) 
 
1.21(0.86, 1.71) 
1.29(0.93, 1.79) 
0.98(0.74, 1.29) 
                     Ref 
0.92(0.52, 1.61) 
Hysterectomy e 0.87(0.77, 0.98) 0.90(0.75, 1.07) Ref 0.90(0.77, 1.04) 0.89(0.72, 1.11)  
Oophorectomy f 0.89(0.78, 1.00) 0.88(0.73, 1.05) Ref 0.86(0.74, 1.00) 0.89(0.71, 1.11) 
 
Reproductive factors were modelled independently and then adjusted for confounders; *adjusted for age at menarche; a 
Ref - >3; b Excluding nulliparous women, Ref – never breastfed; c Ref – No Oral contraceptive use; d Ref- no HRT; e Ref- 
no hysterectomy; f Ref-no oophorectomy  
Multivariate model – adjusted for age, BMI, education, smoking, alcohol consumption, physical activity, diabetes and 
stroke 
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8.8 SUPPLEMENTAL TABLE AND FIGURES 
 
 
Supplemental Figure 8-2: Analysis sample derivation 
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Supplemental Table 8-6: Correlations between reproductive factors 
 
Menarche Parity Breastfeeding OCP Menopause Hysterectomy Oophorectomy 
Menarche 1 0.02 0.04 -0.04 -0.01 -0.03 -0.02 
Parity 
 
1 0.17 0.08 0.07 -0.04 -0.09 
Breastfeeding 
  
1 0.05 0.04 0.01 -0.01 
OCP 
   
1 0.08 -0.01 -0.01 
Menopause 
    
1  N/A -0.06 
HRT 
     
0.04 0.06 
Hysterectomy 
     
1 0.79 
Oophorectomy 
      
1 
Bold indicates significance at p<0.05. 
 
 
 
Supplemental Figure 8-3: Group based trajectories showing maintained (group 1), expected (group 2) and accelerated (group 
3) change in chair stand time 
 
 
60 
9.0  PAPER 2: ASSOCIATION BETWEEN REPRODUCTIVE FACTORS AND 
PREVALENT AND INCIDENT RADIOGRAPHIC HIP OSTEOARTHRITIS 
Nayana Nagaraj, MBBS, MPH1; Robert M. Boudreau, PhD1; Samar R. El Khoudary, 
PhD, MPH, FAHA1; Rebecca C. Thurston, PhD2; Nancy E. Lane, MD3; Michael C. Nevitt, PhD, 
MPH4; Anne B. Newman, MD, MPH1; Jane A. Cauley, DrPH1 
1Department of Epidemiology, Graduate School of Public Health, University of 
Pittsburgh, Pittsburgh, PA; 2Department of Psychiatry, University of Pittsburgh, Pittsburgh, 
PA;3Department of Internal Medicine, Davis School of Medicine, University of California, Davis 
CA; 4Department of Epidemiology & Biostatistics, UCSF School of Medicine, University of 
California, San Francisco, CA; 
 
Contact information (emails): 
Nayana Nagaraj: nayana.nagaraj@pitt.edu 
Robert M. Boudreau: boudreaur@edc.pitt.edu 
Samar R. El Khoudary: elkhoudarys@edc.pitt.edu 
Rebecca C. Thurston: thurstonrc@upmc.edu 
Nancy E. Lane: nelane@ucdavis.edu 
Michael C. Nevitt: michael.nevitt@ucsf.edu 
Anne B. Newman: newmana@edc.pitt.edu 
 
Corresponding author: Jane A. Cauley, Dr.PH, University of Pittsburgh, Graduate School 
of Public Health, Department of Epidemiology, 130 DeSoto Street, Crabtree A510, Pittsburgh, 
PA 15261. jcauley@edc.pitt.edu ; tel, 412-624-3057; fax, 412-624-7397 
 
61 
9.1 ABSTRACT 
Objective: To estimate the association between reproductive history and risk of prevalent and 
incident Radiographic Hip OA (RHOA) in older women. 
Methods: Participants from the Study of Osteoporotic fractures with pelvic radiographs obtained 
at visit 1 and visit 5 (mean 8.3 years apart) were included in the study. RHOA was defined as 
presence of Minimal Joint Space ≤2.5mm at visit 1 (prevalent), visit 5 (incident) and total (visit 
1+5). Information on reproductive history including age at menarche, parity, breastfeeding, age 
at menopause, hysterectomy and oophorectomy were collected from questionnaires. Women who 
reported extremes of age at menarche (<10 or >17) and/or menopause (<30 or >58) were 
excluded to limit bias and increase generalizability. Odds of RHOA and 95% confidence 
intervals for prevalent, incident and total RHOA were estimated using logistic regression. All 
reproductive factors were assessed independently – first by bi-variately and then adjusted for 
age, BMI, education, smoking, alcohol consumption, physical activity, diabetes and stroke.  
Results: Final study population consisted of 4502 women [mean(SD) age=70.7(4.7) years, BMI 
= 26.5(4.5) kg/m2]. Compared to women with 2 children, women with 1 child had greater odds 
of incident [OR(95% CI) = 1.42(1.05, 1.94)] and total RHOA [1.32(1.08, 1.61)], independent of 
the covariates. Women with 4 children had significantly lower odds of total RHOA in unadjusted 
models [0.79(0.63, 0.99)], independent of the covariates. Breastfeeding was associated with 
lower odds of incident RHOA [0.76(0.61, 0.94)]. No significant associations were noted with 
other reproductive factors. 
Conclusion: women with greater parity and a history breastfeeding were associated with a lower 
risk of RHOA in older Caucasian women, independent of age, BMI, education and physical 
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activity. Further research is required to understand underlying mechanisms and extend the 
findings to ethnically diverse populations 
9.2 INTRODUCTION 
Osteoarthritis (OA) is the most common joint disorder in the United States. In 2010, OA 
accounted for about 6.7 million hospitalizations and 21.7 million ambulatory physician visits291. 
Compared to men, women have 45% greater risk of incident knee and 36% greater risk of 
radiographic hip OA (RHOA)120. Coupled with the longer life expectancy, OA in women, is 
associated with greater morbidity292, poor quality of life293, and high economic burden294. 
Determining risk factor for OA is an essential step to be able to design intervention studies that 
could delay the onset or reduce the severity of symptomatic OA.  
Few risk factors have been established in the development of OA. Besides female gender 
and the wear and tear of aging, increased mechanical load on the joints (obesity)140, joint injury 
and low Socio-Economic Status (SES) have been implied as major risk factors295. In some 
individuals, a component of inflammation may also be associated with the development or 
progression of OA165. Local fat hormones like leptin and adiponectin could mediate the 
inflammatory effect. While leptin has shown direct association with the severity of cartilage 
degeneration296, adiponectin may inhibit the progression of osteoarthritis297. 
Despite a greater predilection for OA in women, little is understood about the role of sex-
specific factors, particularly the reproductive health. Early age at menarche298, greater parity136, 
menopausal transition137 and early bilateral oophorectomy138 have been shown to be associated 
with obesity/overweight. Conversely, exclusive breastfeeding aides in postpartum weight loss 
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and return to pre-pregnancy weight299. Low ovarian function and low estrogen levels are also 
associated with greater inflammation160. Put together, these findings suggest a possible 
association between reproductive health and osteoarthritis via biomechanical and inflammatory 
pathways.  
Few studies have evaluated associations between certain reproductive factors and risk of 
replacement or OA, predominantly at the knee. The Million Women Study reported that women 
with early menarche (≤ 11years) had a greater risk of hip (9%) and knee (15%) replacement 
compared to women with   menarche at age 12, independent of age and body mass index 
(BMI)201.  Wise et al, reported that greater parity (>=3 children) was associated with over 2.5 
times greater risk of knee OA and knee replacement compared to one birth, independent of age 
and BMI204. Arden et al, suggested that hormone therapy (HT) may have a protective effect on 
osteoarthritis208. While some studies have supported this hypothesis207, the Women’s Health 
Initiative showed no association between HT and hip or knee replacement209. Some207 but not 
all201 studies demonstrated an association between age at menopause and OA risk. Overall, the 
association between reproductive health and OA is poorly understood. Many of these studies 
were limited by cross-sectional design or short duration of follow up, self-reported OA, and/or 
failed to account for the potential effect of important confounding variables like BMI.  
Female reproductive health acts as the custodian of health and disease in later life300. It is 
important to understand the impact of reproductive health on OA in later life. The existing 
literature is largely limited to changes at the knee. To the best of our knowledge, associations 
between multiple reproductive factors and risk of Hip OA in older women have not been 
previously assessed. We hypothesized that women with early age at menarche, greater parity, 
non-breastfeeding, early age at menopause and non-HT users are at a greater risk of prevalent 
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and incident RHOA. Using the data from the Study of Osteoporotic Fractures, we aimed to 
understand these associations, independent of potential confounders.  
9.3 METHODS 
Study population:  
Study of Osteoporotic Fractures (SOF) was a multi-center longitudinal study of women 
designed to understand the risk factors for osteoporotic fractures258. Women were recruited from 
4 centers across the country (Baltimore, MD; Monongahela Valley near Pittsburgh, PA; 
Minneapolis, MN; and Portland, OR). Eligibility criteria included absence of bilateral hip 
replacement and ability to walk without assistance. At baseline (1986-1988), 9704 ambulatory 
women aged 65 years or older were enrolled. The participants were followed up biennially for 
over 20 years (year 20 exam 2006-08) with clinical visits and examinations. At baseline, only 
Caucasian women (N=9702) were included due to their higher risk of hip fractures. The study 
protocol was approved by the institutional review board of all sites and participants provided 
written informed consent.  
The Hip Osteoarthritis cohort was an ancillary study to SOF. OA status was determined 
from pelvic radiographs. Radiographs were obtained at 2 visits – baseline and again at visit 
5(1995-96). Radiographs from both baseline and visit 5 were available on 5987 women. At 
baseline, radiographs were obtained on all participants (n=9704). At visit 5, radiographs were 
obtained only on 61% of the baseline cohort (7847 women returned at visit 5 (80% of baseline)). 
Additional radiographs were obtained at home visits using portable X-ray machines in women 
who were unable to visit the clinic (n=467)301. As extremes of menarche and menopause are 
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known to be underlying markers for adverse health, the study was limited to menarche between 
10-17 years (n=371) and menopause between 30-58 years (n=1113).  
Of those who were excluded, 436 women had RHOA at baseline. The mean age and BMI 
of the excluded population was 71.3 years and 26.8 kg/m2 respectively. The age at menarche and 
menopause ranged from 9-24 years and 17-62 years respectively. Thus, to improve the internal 
validity of our results, these women were excluded.  
Study measures: 
Radiographic Hip OA: Supine antero-posterior radiographs with 40 inches between the 
film and the focus were obtained at baseline and visit 5. The hips were internally rotated (15-30 
degrees) with the X-ray positioned on the pubis symphysis302. The presence of RHOA was 
determined from radiographs using an atlas303. While many definitions for RHOA were 
available, for the current study we defined RHOA (Yes/No) based on Minimal Joint Space 
(MJS) ≤2.5mm258. MJS was measured as the shortest distance between the acetabulum and 
margin of the femoral head258. This definition has been previously shown to have high 
reproducibility27 and high inter-reader reliability (κ statistic =0.71)258. 
Reproductive factors: Multiple reproductive factors across the life course were included 
to comprehensively characterize a woman’s reproductive history. Age at menarche and 
menopause was self-reported as age at first and last menstrual periods respectively. During the 
reproductive period, information on parity (total number of live births), breast feeding (yes/no) 
and use of birth control pills (yes/no) was collected. Use of hormone therapy (HT) was self-
reported as the use of oral estrogen as current, past or no HT use. Surgical removal of uterus 
(hysterectomy) and ovaries (oophorectomy) were recorded. All reproductive data except age at 
menarche (visit 2) was collected at baseline. Age at menarche, parity and age at menopause were 
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considered as continuous and categorical variables. Age at menarche was classified as 10-11, 12-
13, 14-15 and 16-17 years. Age at menopause was classified in 5-year intervals as ≤40, 41-45, 
46-50, 51-55 and >55 years. Parity was categorized as nulliparous (0), 1, 2, 3, 4 and 5-8 live 
births. 
Other measurements:  
Factors impacting the risk of RHOA were considered, including age at baseline (years), 
education, and BMI. Education was obtained from self-reported highest grade/year of school 
completed. BMI (kg/m2) was calculated as weight (kilograms) divided by height square (meters). 
Smoking status was evaluated as never or ever smoker. Alcohol consumption was self-reported 
as total number of drinks per day in the last 30 days. A modified Harvard alumni questionnaire 
was used to assess physical activity262. Frequency and distance walked every day in city blocks 
or its equivalent was self-reported. In addition, duration of activities like gardening, dancing, 
swimming, aerobics etc. in the last year were reported. Physical activity was calculated as a 
weighted measure of average total kilocalories per week over the past year304. Diabetes and 
stroke were self-reported by the participants. Concurrent information on all factors except 
physical activity and alcohol consumption (from baseline) were used in the analyses.  
Statistical methods:  
Participants with data on reproductive factors and radiological RHOA were included in 
the study. Differences in characteristics of women with prevalent, incident and no RHOA was 
assessed using ANOVA and chi-squared tests for continuous and categorical variables 
respectively. Logistic regression was used to assess the association between the reproductive 
factors and RHOA. The odds of prevalent and incident RHOA were assessed at baseline and visit 
5 respectively.  Total RHOA was assessed as odds of all RHOA (incident and prevalent) at visit 
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5. The reproductive factors were assessed independently – first bi-variately and then adjusted for 
covariates (age, education, BMI, smoking, alcohol consumption, physical activity, diabetes and 
stroke) in the final model. Age at menarche, parity, and age at menopause were assessed both as 
continuous and categorical variables. Age at menarche was categorized by 2-year intervals. 
Parity was classified as nulliparous, 1, 2, 3, 4 and 5-8 children. Age at menopause was 
categorized by 5-year intervals as ≤40, 41-45, 46-50, 51-55 and >55 years. Women who reported 
hysterectomy were excluded from assessment of age at menopause due to limitations in 
accurately estimating age at menopause.  
9.4 RESULTS 
Characteristics of the population by OA status are summarized in Table 9-1. At baseline, 
1265 women had prevalent RHOA with an additional 531 women developing RHOA by visit 5 
(incident). By visit 5, 2706 women remained free of RHOA. Women with prevalent RHOA at 
baseline were significantly older, shorter and had fewer years of schooling compared to women 
in incident and no RHOA groups. No significant differences were noted for BMI, smoking, 
alcohol consumption, diabetes or stroke between prevalent, incident and no RHOA sub-cohorts. 
Interestingly, women without RHOA women had significantly greater parity compared to the 
other 2 groups with fewer nulliparous women and greater proportion of women with 4 children 
or more.  Significant differences in parity were noted between prevalent (mean parity = 
2.67(1.66)) and no RHOA (2.80(1.52)) populations. No significant differences were noted with 
any of the other reproductive factors by OA status.  
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Prevalent RHOA: In unadjusted models (table 9-2), greater parity was associated with 
5% lower odds of RHOA [OR(95% CI) = 0.95(0.91, 0.99)]. However, no significant associations 
were noted using parity as a categorical variable. Menopause ≤40 years [1.28(1.01, 1.63)] was 
associated with 1.28 times greater odds of RHOA. HT use [0.87(0.76, 0.99)] was associated with 
13% lower odds of RHOA. However, these associations were explained by age and education. 
No significant associations were noted with other reproductive factors. 
Incident RHOA: Compared to women with 2 children, women with 1 child [1.44(1.06, 
1.95)] had a 44% greater odds of incident RHOA in the unadjusted models. After accounting for 
potential confounders, the association remained significant [1.42(1.05, 1.94)]. No significant 
associations were noted with the other parity categories in the unadjusted or final models. Breast 
feeding [0.80(0.65, 0.99] was associated with 20% lower odds of incident RHOA.  In the final 
model, a history of breastfeeding was associated with 24% lower odds of RHOA [0.76(0.61, 
0.94]. No associations were noted with age at menarche, oral contraceptive pill use, HT use, age 
at menopause, hysterectomy or oophorectomy and incident RHOA. 
Total RHOA: Combining women with either prevalent or incident RHOA (N= 1796) 
showed similar associations with parity, i.e., greater parity [0.95(0.91, 0.99)]. Parity was 
associated with 5% decreased odds of RHOA in the unadjusted models. The association was 
explained by accounting for age. Compared to parity of 2, women with 1 child [1.36(1.12, 1.66)] 
had 36% greater odds of RHOA, compared to women with 2 children. This association 
attenuated but remained significant in the final model [1.32(1.08, 1.61)]. Interestingly, compared 
to women with 2 children, women with 4 children had a 24% [0.76(0.61, 0.95)] decreased odds 
of OA in the unadjusted model. This association attenuated to 21% [0.79(0.63, 0.99)] after 
69 
adjustment for confounders. No associations were noted with age at menarche, breastfeeding, HT 
use, age at menopause or hysterectomy/oophorectomy and total RHOA. 
9.5 DISCUSSION 
Our study showed associations between early life reproductive factors like parity and 
breastfeeding on the development of RHOA in older age. Greater parity measured as a 
continuous variable was associated with lower risk of both prevalent and total RHOA. Compared 
to the referent (parity = 2), women having 1 child had greater risk of incident (42%) and total 
(32%) RHOA, while having 4 children had a lower risk of total (21%) RHOA. These 
associations were independent of age, education, BMI, smoking, alcohol consumption, physical 
activity, diabetes and stroke. Although not all parity groups reached significance, it is likely that 
the association between parity and risk of RHOA is non-linear with greatest risk among women 
with 1 child and lowest for women with 4 children. Additionally, history of breastfeeding was 
associated with 24% lower risk of incident RHOA independent of confounders and parity 
(results not shown). No associations were noted with the other reproductive factors. To the best 
of our knowledge, no other study has assessed the association between reproductive factors and 
RHOA in older women.   
Current literature is limited to knee OA and knee/hip replacement. In a prospective study 
of middle aged women (mean age = 56 years) from the Million Women’s Study, Lui et al201, 
reported a 2% and 8% per birth increase in risk of hip and knee replacement respectively. 
Compared to nulliparous women, women with 4 or more children had a 10% greater risk of hip 
replacement. No significant associations were noted for women having 1, 2 or 3 children. 
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Conversely, 21% - 46% increased risk of knee replacement was noted for women with parity of 
1- 4 or more. Women who underwent replacement were more likely to be older and of low SES. 
The authors attributed these associations largely to obesity and increases in BMI with greater 
parity and low SES. However, the due to limited information, the authors could not assess the 
association with risk of osteoarthritis, nor account for confounding effects of education and 
physical activity. Wise et al., studied women from the Multicenter Osteoarthritis Study cohort 
(MOST) (mean age = 62.6 years) and extended the findings to knee OA. Knee OA was assessed 
from X-ray radiographs using Kellgren/Lawrence grade ≥ 2. They reported that greater parity 
was associated with a greater risk of both incident radiologic knee OA and knee replacement204. 
These associations were independent of many confounders including BMI, pain, occupation, 
hormone therapy and any knee injury. The authors proposed a multi-hit model and suggested a 
combination of obesity and lifestyle factors resulting in an increased risk of OA. Increase in BMI 
with parity203, and additional insults from caring for children during childbearing years could 
manifest as knee OA in older age. A recent Korean study (≥50 years) reported a stronger 
association between knee OA and parity in women who had undergone abortion (pregnancy ≤ 7 
months)305 [Knee OA, from X-ray radiographs, defined as Kellgren/Lawrence grade of 1 or 
more]. In addition, they also reported but failed to explain why the association was weaker in 
women with greater number of abortions. They hypothesized that sudden physical/hormonal 
changes from abortions could exert greater stress on cartilage than pregnancy only. Many other 
studies have demonstrated no association between parity and knee OA211,212. A few different 
reasons may be for the contradiction with existing studies on knee OA. The Million women 
study had limited information on other causes of RHOA like occupation history and joint injury. 
In addition to degenerative joint diseases like OA, repeated injury to the joint and occupation are 
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important risk factors for joint replacement204. Interestingly, studies in the United States have 
reported lower rates of joint replacement in lower SES men and women, potentially due to 
disparity in access to care202. This observation is contrary to England and Scotland where the 
healthcare system is centralized306. The MOST study included women with risk factors for knee 
OA including obesity, knee injury, and knee pain or stiffness in the last 30 days. Thus, it is likely 
that the sample was not representative of the general population204.  
In contrast to the findings at the knee joint, our results demonstrated a decreased risk of 
RHOA in older women with greater parity and breastfeeding. Biomechanical changes during 
pregnancy may be responsible for the differential association of parity between hip and knee OA. 
With the increase in weight during pregnancy, the center of gravity shifts upwards and 
forwards307,308. To control the center of gravity, the spine is thrown into lordosis (bending), 
resulting in greater biomechanical insults307. Increase in the lumbar lordosis and the anterior 
pelvis tilt could move the move the center of gravity to behind the hip joint and anterior to the 
knee joint309. Such a shift may could result in increased load at the knee joint310 and slightly 
reduced load at the hip.  In addition, the hormone relaxin, may produce ligament laxity in the 
pelvis and other joints311 during late pregnancy. Relaxin, along with estrogen has shown to 
decrease inflammation in human cells312 and arthritis induced rat models313. Additionally, in a 
small study of 68 women, Calguneri et al, demonstrated that with greater parity, correlation 
between relaxin and laxity was higher314. Put together, relaxin may play an important role in the 
association between greater parity and lower risk of RHOA via the inflammatory pathway. 
Similar mechanisms may be attributable to the association between breastfeeding and RHOA. 
Anti-inflammatory advantages of breastfeeding are well documented163 and may be protective 
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against RHOA. No information on duration of breastfeeding was available to assess this 
association further. 
It may be interesting to note that of all the reproductive factors, only parity differed 
significantly across the 3 RHOA groups. It is also important to note that SOF participants were 
relatively healthy and well-functioning at baseline, partly due to how the study was designed. 
Although greater parity was associated with slightly greater BMI, no significant association was 
noted between concurrent BMI and risk of RHOA. In addition, the sub-populations by parity 
groups were likely very small to demonstrate significant results. Nevertheless, a significant non-
linear trend (p<0.01) between parity groups and prevalent, incident and total RHOA were noted. 
Interestingly, no associations were noted between HT use, age at HT initiation or duration of HT 
use.  
The study had many strengths. The SOF study collected information on a large 
community based cohort of older women, around the age of peak incidence of RHOA198. We had 
information on a large number reproductive factors. We had no information on weight gain with 
each pregnancy. The study population was limited to Caucasian women. The results therefore, 
may not be generalizable to other race/ethnic groups. Radiographs were available only at 
baseline and visit 5. Thus, the timing of “incidence” of hip OA may not be accurately assessed. 
The reproductive history was assessed from questionnaires and maybe subject to recall bias. 
Simultaneous comparison of many reproductive factors may pose a problem of multiplicity. 
Nonetheless, to the best of our knowledge, no other studies have assessed have assessed the 
associations between reproductive history and radiologically defined RHOA. 
In summary, women with greater parity and a history breastfeeding were associated with 
a lower risk of RHOA in older Caucasian women, independent of age, BMI, education and 
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physical activity. Future work should consider potential mechanisms linking parity and 
breastfeeding with RHOA (e.g., biomechanical changes during pregnancy and anti-inflammatory 
properties of breastfeeding) as well as extend this work to more ethnically diverse study 
populations.  
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9.6 TABLES 
Table 9-1: Concurrent characteristics of the population by OA status 
  Prevalent Hip OA 
(visit 1) (N=1265) 
Incident Hip OA 
(visit 5) (N=531) 
No Hip OA (visit 5) 
(N=2706) 
p-value 
Age (years) 71.52(5.03) 71.08(4.83) 70.3(4.41) <0.0001 
Education (years) 12.59(2.86) 13.13(2.69) 12.85(2.73) 0.0004 
Height (cm) 158.45(6.17) 159.9(5.89) 159.69(5.86) <0.0001 
Weight (kg) 66.79(12.66) 67.68(11.65) 67.52(12.09) 0.17 
BMI (kg/m2) 26.59(4.73) 26.48(4.37) 26.47(4.45) 0.71 
Ever smoker N(%)          455(36.14) 199(37.69) 1044(38.64) 0.31 
Alcohol consumption (drinks/week 
adjusted for atypical drinks)*  1.82(3.91) 
  
2.00(3.91) 
  
1.88(3.78) 
  
0.64 
Physical activity (kcal/week last year) 1649.90(1653.11) 1805.46(1821.63) 1767.11(1589.47) 0.07 
Diabetes N(%) 63(4.98) 24(4.53) 140(5.19) 0.81 
Age at menarche (years) 13.06(1.37) 12.96(1.37) 13.02(1.37) 0.41 
Menarche (years) N(%) 
        10-11 
        12-13 
        14-15  
        16-17 
  
152(12.02) 
675(53.36) 
371(29.33) 
67(5.30) 
  
62(11.68) 
310(58.38) 
129(24.29) 
30(5.65) 
  
319(11.79) 
1504(55.58) 
735(27.16) 
148(5.47) 
0.47 
Parity  2.67(1.66) 2.67(1.63) 2.8(1.52) 0.0351 
Parity N(%)** 
         Nulliparous 
         1 
         2 
         3 
         4 
         5-8 
  
38(3.56) 
194(18.20) 
353(33.11) 
236(22.14) 
122(11.44) 
123(11.54) 
  
13(2.97) 
82(18.72) 
136(31.05) 
113(25.80) 
46(10.50) 
48(10.96) 
  
62(2.70) 
312(13.58) 
743(32.33) 
569(24.76) 
344(14.97) 
268(11.66) 
0.0015 
Breast fed N(%)* 736(69.04) 285(65.07) 1604(69.86) 0.14 
Oral contraceptive user N(%) 57(4.52) 25(4.71) 143(5.29) 0.55 
HT use, ever, N(%) 495(39.70) 226(43.13) 1155(43.19) 0.11 
Age at HT initiation (years) 50.37(8.56) 49.42(7.28) 50.44(7.91) 0.23 
Age at HT initiation, N(%)  
       ≤50 years  
       >50 years 
 
280(59.70) 
189(40.30) 
 
138(64.19) 
77(35.81) 
 
642(57.42) 
476(42.58) 
0.16 
Duration of HT use (years) 7.50(8.23) 8.37(8.55) 7.29(7.74) 0.19 
Duration HT use, N(%)  
       <=5 years  
       >5 years     
 
242(51.49) 
228(48.51) 
 
95(44.19) 
120(55.81) 
 
571(50.89) 
551(49.11) 
0.16 
Age at menopause (years) 48.14(5.31) 48.38(4.81) 48.3(5) 0.56 
Menopause (years) N(%) 
        <=40  
        41-45 
        46-50 
        51-55 
        >55 
  
136(10.75) 
223(17.63) 
492(38.89) 
368(29.09) 
46(3.64) 
  
39(7.34) 
107(20.15)                   
212(39.92) 
156(29.38) 
17(3.20) 
  
235(8.68) 
537(19.84) 
1045(38.62) 
795(29.38) 
94(3.47) 
0.34 
Hysterectomy N(%) 346(27.35) 140(26.37) 685(25.32) 0.39 
Oophorectomy N(%) 305(24.72) 127(24.42) 657(24.92) 0.97 
*significant difference between prevalent vs no RHOA; *excluding nulliparous women 
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Table 9-2: Association between reproductive factors and risk of hip OA 
 Prevalent Hip OA (N=1265) Incident Hip OA (N=531) Total hip OA (N=1796) 
   
Unadjusted 
[OR (95% CI)] 
Fully adjusted1 
[OR (95% CI)] 
Unadjusted 
[OR (95% CI)] 
Fully adjusted1 
[OR (95% CI)] 
Unadjusted 
[OR (95% CI)] 
Fully adjusted1 
[OR (95% CI)] 
Age at menarche Continuous 1.03(0.98, 1.08) 1.01(0.96, 1.06) 0.97(0.91, 1.04) 0.98(0.91, 1.05) 1.01(0.96,1.05) 1.00(0.96, 1.05) 
Age at menarche 
10-11 
12-13 [ref] 
14-15 
16-17 
1.07(0.87, 1.32) 
Ref 
1.15(0.99, 1.34) 
1.01(0.75, 1.36) 
1.06(0.86, 1.31) 
Ref 
1.10(0.94,1.28) 
0.95(0.71, 1.29) 
0.94(0.70, 1.27) 
Ref 
0.85(0.68, 1.07) 
0.98(0.65, 1.48) 
0.92(0.68, 1.24) 
Ref 
0.83(0.66, 1.05) 
1.02(0.67) 
1.04(0.86, 1.25) 
Ref 
1.04(0.91, 1.20) 
0.99(0.76, 1.30) 
1.02(0.84, 1.24) 
Ref 
1.01(0.87, 1.16) 
0.97(0.74, 1.28) 
Parity Continuous 0.95(0.91, 0.99) 0.97(0.92, 1.01) 0.94(0.88, 1.01) 0.96(0.90, 1.03) 0.95(0.91, 0.99) 0.97(0.93, 1.01) 
Parity 
0 
1  
2 [ref] 
3 
4 
5-8 
1.26(0.84, 1.90) 
1.23(0.99, 1.52) 
Ref 
0.86(0.71, 1.05) 
0.78(0.61, 0.99) 
0.97(0.76, 1.24) 
1.30(0.85, 1.96) 
1.17(0.95, 1.45) 
Ref 
0.88(0.72, 1.07) 
0.81(0.64, 1.04) 
1.01(1.03, 1.06) 
1.15(0.61, 2.14) 
1.44(1.06, 1.95) 
Ref 
1.09(0.83, 1,43) 
0.73(0.51, 1.05) 
0.98(0.68, 1.40) 
1.14(0.60, 2.15) 
1.42(1.05, 1.94) 
Ref 
1.13(0.85, 1.48) 
0.74(0.51, 1.07) 
1.07(0.51, 1.07) 
1.27(0.86, 1.88) 
1.36(1.12, 1.66) 
Ref 
0.94(0.79, 1.12) 
0.76(0.61, 0.95) 
1.00(0.80, 1.26) 
1.29(0.87, 1.92) 
1.32(1.08, 1.61) 
Ref 
0.97(0.81, 1.16) 
0.79(0.63, 0.99) 
1.07(0.85, 1.34) 
Breast feeding Yes No [ref] 
0.99(0.86, 1.16) 
Ref 
0.94(0.81, 1.10) 
Ref 
0.80(0.65, 0.99) 
Ref 
0.76(0.61, 0.94) 
Ref 
0.92(0.80, 1.06) 
Ref 
0.87(0.75, 1.00) 
Ref 
Oral contraceptive 
use 
Ever 
Never[ref] 
0.86(0.64, 1.18) 
Ref 
1.07(0.78, 1.46) 
Ref 
0.88(0.57, 1.37) 
Ref 
0.97(0.62, 1.51) 
Ref 
0.86(0.65, 1.14) 
Ref 
1.03(0.77, 1.37) 
Ref 
Hormone Therapy 
use  
Ever 
Never [ref] 
0.87(0.76, 0.99) 
Ref 
0.96(0.83, 1.10) 
Ref 
1.00(0.83, 1.21) 
Ref 
1.02(0.84, 1.24) 
Ref 
0.92(0.81, 1.04) 
Ref 
0.98(0.87, 1.12) 
Ref 
Age at menopause Continuous 0.99(0.98, 1.01) 0.99(0.98, 1.01) 1.00(0.98, 1.02) 1.00(0.98, 1.02) 1.00(0.99, 1.01) 1.00(0.99, 1.01) 
  
Age at menopause 
<=40 
41-45 
46-50  
51-55 [ref] 
>55 
1.28(1.01, 1.63) 
0.90(0.74, 1.09) 
1.01(0.86, 1.19) 
Ref 
1.07(0.74, 1.54) 
1.18(0.92, 1.50) 
0.86(0.71, 1.05) 
0.97(0.82, 1.14) 
Ref 
1.07(0.74, 1.55) 
0.87(0.59, 1.27) 
1.03(0.79, 1.36) 
1.05(0.83, 1.31) 
Ref 
0.94(0.54, 1.61) 
0.87(0.59, 1.28) 
1.03(0.78, 1.35) 
1.04(0.83, 1.31) 
Ref 
0.97(0.56, 1.68) 
1.12(0.89, 1.40) 
0.93(0.78, 1.12) 
1.03(0.89, 1.19) 
Ref 
1.03(0.74, 1.45) 
1.10(0.87, 1.38) 
0.91(0.76, 1.09) 
1.00(0.86, 1.16) 
Ref 
1.06(0.75, 1.49) 
Hysterectomy Yes  
No [ref] 
1.10(0.95, 1.27) 
Ref 
1.10(0.95,1.28) 
Ref 
1.05(0.85, 1.30) 
Ref 
1.06(0.74, 1.83) 
Ref 
1.09(0.95, 1.24) 
Ref 
1.09(0.95, 1.25) 
Ref 
Oophorectomy Yes 
No [ref] 
0.99(0.85, 1.16) 
Ref 
1.01(0.87, 1.18) 
Ref 
0.98(0.79, 1.22) 
Ref 
1.00(0.80, 1.25) 
Ref 
0.98(0.85, 1.13) 
Ref 
1.01(0.87, 1.16) 
Ref 
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1Fully adjusted model – adjusted for age, BMI, education, smoking, alcohol consumption, physical activity, diabetes and stroke  
*adjusted for age at menarche; a Ref - >3; b Ref – never breastfed; c Ref – No Oral contraceptive use; d Ref- no HRT; e Ref- no hysterectomy; f Ref-no oophorectomy  
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10.1 ABSTRACT 
Objective: To understand the associations of reproductive factors and sex-hormones with hip 
geometry [from Hip Structural Analysis (HSA)] relative to the final menstrual period (FMP). 
Methods: At baseline, 1947 women from SWAN bone cohort were included. For longitudinal 
analyses (spanning across 10 years), women with information on final menstrual period (FMP) 
and more than 1 DXA scan were included (N=900). Hormone therapy users were excluded from 
the analyses. HSA parameters at femoral narrow neck [Bone Mineral Density (BMD), Cross 
Sectional Area (CSA), Section Modulus (SM), Outer Diameter (OD) and Buckling ratio (BR)] 
were obtained from 2D DXA scans and normalised to baseline values. Reproductive factors 
(menarche, parity, breastfeeding, age at first and last birth, and OC use) were self-reported. Sex 
hormones [estradiol (E2), Follicle Stimulating Hormone (FSH), testosterone (T) and Sex-
Hormone Binding Globulin (SHBG)] were measured from blood samples drawn annually. 
Associations between reproductive factors and pre-menopausal HSA were assess using linear 
regression models. Mixed effects linear model with random slopes were used to estimate the rate 
of change in HSA. Changes in HSA were assessed over 3 phases, 5 to 2 years before FMP (pre-
transmenopausal), 2 before to 1 years after FMP (transmenopausal), 1 to 5 years after FMP 
(postmenopausal). Reproductive factors and sex-hormones were assessed independently and 
subsequently adjusted for baseline age, race, education, smoking, physical activity, and time 
varing BMI and diabetes status. 
Results: At baseline, later age at last birth and OC use were associated with greater CSA and 
lower OD levels respectively. Over the 10 year period, only breastfeeding was associated with 
accelerated decline in BMD (-2.21%/10 years), and CSA(-1.82%) and accelerated increase in 
OD(0.59%) and BR(0.25%). Doubling of FSH and SHBG were associated with faster loss of 
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BMD, CSA and SM with accelerated increase in BR cumulatively. However, these associations 
were not consistent across all phases. These associations were independent of covariates. 
Associations with SHBG were independent of E2 or T levels. 
Conclusions: Doubling of FSH and SHBG were associated with unfavourable HSA changes 
cumulatively but not all phases of the menopausal transition. Further research to understand the 
underlying mechanisms could help design targetted interventions to prevent bone loss and 
fractures in later life. 
10.2 INTRODUCTION 
Bones undergo constant modelling and remodeling across female reproductive life220. 
Reproductive events including menarche315, pregnancy316,317, breastfeeding316,317 and 
menopause318 are endocrinologically charged and bear significant effects on bone health. Nearly 
a third of peak bone mineral density (BMD) is gained around menarcheal age220. Pregnancy and 
lactation represent periods of increased calcium demand, with increase in intestinal calcium 
absorption and bone resorption and decrease in calcium excretion to accommodate this 
need316,317,319,320. Decline in estradiol (E2) and rise in follicle stimulating hormone (FSH) over 
the Menopausal Transition (MT), have been shown to be associated with accelerated loss of 
lumbar spine BMD starting 1 year before to 2 years after final menstrual period (FMP)129. Thus 
increasing the risk of fractures in the post-menopausal period. Hip fracture is of the most 
common osteoporotic fractures in older women, with significant functional limitations and high 
1-year mortality (>20%) following it321,322. 
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However, fracture risk and bone strength depends on both density and bone quality, i.e., 
bone microarchitecture and geometry323. Areal BMD (aBMD), a 2 dimensional measure of bone, 
fails to account for the bone size and geometry. These structural components, may be a predictor 
of fracture risk in postmenopausal women324. Some227, but not all325 studies have shown this 
association to be independent of aBMD. While the impact of female reproductive health on 
aBMD have been well studied317,318,326, few studies have assessed the association between 
reproductive health and bone geometry. Fels Longitudinal Study assessed metacarpal hip 
geometry from radiographs and reported that later age at menarche was associated with greater 
bone strength in young adulthood.This association was independent of prepubertal bone 
strength315. A cross-sectional study of 87 women in India (aged 55-79 years) reported inverse 
association between parity and cross sectional area (CSA) at narrow neck of the femur232. A 
longitudinal study of lactating mothers reported significant decline in femoral BMD and CSA 
from 2 weeks postpartum to peak lactation, independent of BMI237. Longer years of menstruation 
in postmenopausal Chinese women (mean age = 59.6 years) was also associated with more stable 
bone geometry245. However, little is known about the effect of these reproductive factors on 
change in hip geometry during the menopausal transition.  
Previous findings from Study of Women’s Health Across the Nation (SWAN), has shown 
that during the menopausal transition (MT), change in hip geometry parallels change in aBMD127 
and Femoral Neck (FN) strength243. Hip geometry, measured by Hip Structural Analysis 
(HSA)230, showed accelerated change starting 2 years before to 1 year after menopause which 
continued for 4 more years244. Accelerated increase in Buckling Ratio (BR) and Outer Diameter 
(OD), coupled with accelerated loss of BMD, Cross Sectional Area (CSA) and Section Modulus 
(SM) during the MT could result in cortical instability. Change in sex-steroid hormones were 
significantly associated with the change in aBMD at the lumbar spine. However the effect of 
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reproductive factors and sex-steroid hormones on the HSA change during MT is unknown. Using 
data from the SWAN, we assessed the associations between reproductive factors and sex-steroid 
hormones with pre-menopausal HSA levels and the rate of change HSA during the MT in 
midlife women. 
10.3 METHODS 
Study population: 
SWAN is an ongoing, community based, multi-center, longitudinal study of midlife 
women designed to study the biological, physiological and psycho-social changes during their 
middle years327. The study was started in 1994 and is currently in its 22nd year. The study 
recruited 3302 participants from 7 sites across the US – Ann Arbor, MI; Boston, MA; Oakland, 
CA Chicago, IL; Los Angeles, CA; Newark, NJ & Pittsburgh, PA. Women were eligible to 
participate in the study if they had - (1) at least 1 menstrual period within the past 3 months; (2) 
not pregnant or breast feeding; (3) an intact uterus and at least 1 ovary; (4) no hormone therapy 
use within the past 3 months. The study protocol was approved by the institutional review board 
and informed consent was obtained from all the participants.  
Only 5 out of 7 sites - Los Angeles, CA; Ann Arbor, MI; Boston, MA; Oakland, CA; & 
Pittsburgh, PA sites were included in the bone cohort (N=2335 from visit 1 - visit3). Black 
women were recruited from Ann Arbor, Boston, Chicago and Pittsburgh sites. Japanese and 
Chinese women were recruited from Los Angeles and Oakland sites respectively. White women 
were enrolled at all the sites. Women could participate in the bone study if they were (1) enrolled 
in the SWAN main cohort (2) weighed <136 kg (machine limit) and (3) provided informed 
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consent. As an extension to the bone study, hip bone strength was also measured across the 
menopausal transition. For the current study, baseline population included 1947 women with 
information on reproductive factors. Women who had a date for the final menstrual period 
(FMP) were included in longitudinal analyses. Additionally, women were excluded if they 
reported hormone therapy use or had only 1 DXA scan in 10 years (n=27). The longitudinal 
evaluation included 900 women (supplementary figure 10-1).  
Compared to the FMP cohort, the women who were excluded were slightly younger and 
heavier at baseline [mean(SD) age of 46(2.7)years, BMI 27.59(6.8)kg/m2]. Nearly 81% of this 
population had more than high school education, compared to ~76% in the FMP cohort. At 
baseline, women who were excluded had slightly higher BMD, CSA and SM and lower OD and 
BR, compared to the FMP cohort. Interestingly, those who were excluded had lower levels of 
E2, FSH, T and SHBG at baseline.   
Study measures: 
DXA scans: 
Femoral Neck (FN) DXA scans were obtained at every clinic visit using OsteoDyne’s 
Hip Positioner System (Osteodyne Inc, NC) and Hologic QDR scanners (Hologic, Inc., Bedford, 
MA). The Oakland and Pittsburgh sites upgraded from 2000 to 4500 Hologic scanner at visit 8. 
The other 3 sites used 4500A scanner model from baseline to visit 10. Scans on 40 women from 
the 2000 and 4500A machines were used to develop calibration equations. In collaboration with 
Synarc Inc, quality check was conducted through everyday phantom measurements, central 
review of scans flagged for problems, cross site calibration of scans with anthropometric spine 
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standard biannually, local review of all scans and central review of random scans (5%). FN 
measurement variability in vivo was 0.016 g/cm2(2.2%)318.  
Hip geometry (HSA): 
HSA was measured from de-identified DXA scans using software developed at Johns 
Hopkins School of Medicine231. HSA software uses bone mass image from the DXA scan to 
produce areal mass (g/cm2) using pixel values231. It analyzes the geometry at 3 locations on the 
femoral bone –shaft, inter-trochanteric and Narrow Neck (NN) regions. For the current analyses 
only NN measures were used. NN represents the narrowest diameter of the FN. Five measures of 
HSA at the NN were included – Bone Mineral Density(BMD), Cross Sectional Area (CSA), 
Outer Diameter (OD), Section Modulus (SM) and Buckling Ratio (BR). BMD was measured as 
the mean pixels in the region profiles. CSA was the cortical equivalent of cross-sectional bone 
surface area not including the soft tissue and trabecular space. OD was measured as width of 
mass profile after blur correction. SM, an indicator of maximum bending stress was measured as 
a composite measure of cross sectional moment of inertia and distance from outer cortex to the 
mass center. BR is a measure of cortical stability in buckling. It was measured as the relative 
thickness of the cortex231.  
To account for the differences in geometry between the QDR 2000 and QDR4500 
scanners, a linear correction was undertaken. The correction factor was calculated as the ratio of 
NN BMD from QDR 2000 to QDR 4500 prior to visit 8. No significant differences in age, 
weight, and height were noted between the QDR 2000 and QDR 4500 scanners. The resulting 
correction was then applied to the measures from QDR2000 scanner only. To account for any 
residual error, all analysis was adjusted for scanner type.  
84 
Reproductive factors:  
SWAN collected data on multiple reproductive factors. Age at menarche was defined as 
the age when the periods or menstrual cycles started. Age at menarche was assessed as a 
continuous and categorical variable (9-10, 11-12, 13-14, 15-16 years) to understand differences 
between groups. Parity was self-reported as the total number of pregnancies that resulted in a 
livebirth. Parity was assessed continuously and subsequently categorized as nulliparous, 1-3 
births and ≥4 births. For livebirths, data on breastfeeding (yes/no) and duration of breastfeeding 
(months) for each child was self-reported at baseline. Total duration of breastfeeding was 
calculated as the sum of breastfeeding duration for all livebirths, in years. Age at first and last 
birth (years) was also self-reported at baseline. Self-reported use of oral contraceptive pill 
(yes/no) at baseline was included.  
Age at FMP was self-reported on annual follow up interviews as the age at last menstrual 
period reported immediately before being classified as postmenopausal (12 consecutive months 
of amenorrhea).  
Sex-steroid hormones: 
Fasting blood draw was scheduled to occur before 10AM in early follicular phase in (day 
2-5) of the menstrual cycle in menstruating women. Blood draw was arranged within 2 months 
of recruitment at baseline and every follow up visit thereafter91. Fasting blood samples were 
drawn on day 2-5 of the menstrual cycle in menstruating women.  If a timed sample (before 10 
AM in early follicular phase) was not obtainable after 2 attempts, a random sample was drawn 
within 90 days of the baseline visit anniversary. Hormone levels were measured at the Central 
Ligand Assay Satellite Services (CLASS) Laboratory, University of Michigan. Estradiol (E2) 
levels were measured using modified ACS-180 (E2-6) immunoassay (Bayer Diagnostics Corp, 
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Norwood, MA). E2 was measured in duplicate and average of the 2 levels was used. Averaged 
intra and inter-assay coefficients of variation were 6.4% and 10.6% respectively91,329. Serum 
Follicle-Stimulating Hormone (FSH) was measured using a 2-site chemiluminometric manual 
assay kit (Bayer diagnostics). Intra and inter-assay coefficient of variation were 6% and 12% 
respectively91. Lower limit of detection (LLD) ranged from 1-7 pg/ml and 0.4-1 mIU/ml for E2 
and FSH respectively.  
Testosterone (T) levels were assessed using the ACS-180 total T immunoassay329. The 
intra and inter-assay coefficients of variation were 9.7% and 11.3% respectively329. Serum Sex-
Hormone Binding Globulin (SHBG) concentrations were measured using 2 site 
chemiluminescent immunoassay. Intra and inter-assay variability coefficients were 9.9% and 
6.1% respectively. LLD for T and SHBG ranged between 2-2.2 ng/dL and 1.9-3.2 nM 
respectively329. Any assay below the LLD was set to a random level between 0 and the LLD. 
Cycle day of sample collection was recorded as within or outside of the follicular phase (day 2-5) 
for regular menstrual cycles and as unknown for non-menstruating or irregularly menstruating 
women.  
Other factors: 
Information at baseline including age, race, education were self reported on 
questionnaires at baseline. Four races/ethnicities were self reported as – black, white, Chinese 
and Japanese. Education was classified as high school or less and greater than high school. 
Anthropometric measures like height (cm), weight (kg) and body mass index(kg/m2) was 
obtained at each follow up clinic visit. Smoking status was self reported at baseline as current, 
past or never smokers. Baseline physical activity was quantified using modified Baecke score. 
The score is a measure of active living, home and recreational activity330. Diabetes status was 
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obtianed at every follow up visit as self reported diabetes status, fasting glucose level and/or use 
of anti-diabetic medication. 
Statistical Analyses: 
Baseline associations between reproductive factors, sex hormones and hip geometry were 
estimated using linear regression models. The associations were assessed independently and 
subsequently adjusted for potential confounders at baseline (age, race, site, education, BMI, 
smoking status, physical activity and diabetes).  
Longitudinal assessment:  HSA measures were assessed as percent change from baseline 
during the menopausal periods and overall[{ }*100]. To assess the associations 
between reproductive factors, sex hormones and hip geometry over MT we used linear mixed 
models. Time was centered around the final menstrual period (FMP) such that FMP is time 0. 
Step 1 - Locally weighted scatterplot smoothing (LOESS) curves were used to determine the 
trajectory of the HSA measures. Step 2 - Based on the curves, 2 distinct knots – 2 years before 
FMP and 1 year after FMP were noted. Appropriateness of the knots was tested using null 
models at 6 month increments. With these knots, the changes in hip geometry were assessed at 3 
distinct phases – (1) premenopausal (5 years before to 2 years before FMP), (2) transmenopausal 
(2 years before to 1 year after FMP) and (3)post-transmenopausal (1 year to 5 years after FMP). 
Step 3- Using piecewise linear mixed regression, the associations of the reproductive factors and 
sex hormones (annually obtained repeated measures) with the rate of change of each HSA 
measures were estimated244. Rate of change in HSA measures over time were estimated using 
intereaction with time segments. To account for between women heterogeneity, random slopes 
were allowed. The associations were assessed in 2 models. Model 1 was adjusted for site, 
scanner change and baseline value and subsequently adjusted for potential confounfers - age, 
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race, education, BMI, smoking status, physical activity and diabetes. Baseline values for age, 
race and education were used. BMI and diabetes were used as time varying measures. Variation 
in smoking and physical activity over time was not associated with any of the HSA measures and 
hence baseline values were used in the analyses. Change in DXA scanner and baseline value of 
the HSA measure were also accounted for. In addition to phase specific slopes, cumulative 
change over the 10 years was assessed. Reproductive factors and sex hormones were modelled as 
independent predictors for each HSA measure. 
For baseline and longitudinal assessments, nulliparous women were excluded from 
models assessing breastfeeding, age at first and last birth. Repeated measures of hormones were 
used. Given the skewed distribution of the hormones, they were log transformed to base 2. The 
transformation to log base 2 allows for a more intuitive interpretation compared to the natural log 
- one unit increase in log base 2 of the hormones is equal to doubling of the untransformed 
hormone level8. Models assessing hormones were additionally adjusted for cycle day on which 
the blood was drawn. SHBG models were additionally adjusted for E2 levels. 
10.4 RESULTS 
At baseline [Table 10-1], the mean age of the cohort was 46.38 years with a mean BMI of 
27.55 kg/m2. Nearly 50% of the population was White with ~27% Blacks. Over 78% of the 
women had more than high school education with 15% current smokers. The average age at 
menarche was 12.48 years with nearly 71% of the cohort having 1-3 children. Post exclusion of 
nulliparous women, 69% of the women breastfed their offspring, for an average duration of 
about 3/4th of a year.  
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Baseline analyses: 
Later age at menarche, greater parity, later age at last birth, and breastfeeding were 
associated with significantly lower BMD and CSA, in the unadjusted models [Table 10-2].  Later 
age at first birth was associated with lower BMD and CSA. In the fully adjusted model, no 
significant associations were noted with BMD. The associations were explained by age, race, 
BMI and physical activity. After adjusting for confounders, later age at last birth was associated 
with greater CSA. No other reproductive factors/ hormones were associated with CSA.  
In the unadjusted models, T doubling was associated with greater OD. This association 
remained significant in the multivariable model.  Only in the fully adjusted model, OC use was 
associated with lower OD. This reverse confounding effect was explained by smoking. No 
associations were noted with the other reproductive factors or hormones.  
In the unadjusted models, later age at menarche, later age at first birth and ever 
breastfeeding were associated with lower SM while greater parity was associated with greater 
SM. Doubling of FSH and SHBG were associated with lower SM. After accounting for 
confounders, later age at menarche was associated with greater SM. This reversal was explained 
by race, BMI, physical activity. 
Later age at menarche, greater parity, breastfeeding and longer duration of breastfeeding 
were associated with greater BR. Greater FSH, T, and SHBG levels were associated with greater 
BR. In the fully adjusted models, associations with FSH and SHBG were attenuated but 
remained significant. No associations were noted with the other reproductive factors or 
hormones. 
Longitudinal assessment:  
In the fully adjusted models [Tables 10-3], only age at first birth and breastfeeding were 
significantly associated with change in BMD. Later age at first birth was associated with 
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significant decline in the transmenopausal period (-0.04%/year) but not cumulatively. over 10 
years. Breastfeeding was associated with greater declines inBMD during the  transmenopausal 
period (-0.50) and cumulatively (-2.21%/10 years). Doubling of FSH (-0.30%/year) was 
associated with greater BMD loss in the transmenopausal and postmenopausal period 
respectively. These associations also reflected cumulatively over 10 years (-1.12 for FSH and -
0.86 for SHBG). Adjusting for E2 levels, slightly attenuated association between SHBG and 
BMD cumulatively (-0.84). No associations were noted with other reproductive factors/ 
hormones.  
Similar patterns were noted for CSA [Tables 10-4]. Later age at first birth was associated 
with greater loss in the transmenopausal period (-0.04). No significant cumulative association 
was noted. Breastfeeding was associated with significant greater CSA loss cumulatively (-
1.82%/10 years). Doubling of E2 was associated with lower CSA loss (+0.14%/year) in the 
transmenopausal period but not cumulatively. Conversely, doubling of FSH was associated with 
greater loss of CSA in the transmenopausal period (-0.28) and over 10 year (-1.16%/10 years). 
Doubling of SHBG was associated with greater loss of CSA in the postmenopausal period (-
0.23%/year) and cumulatively (-0.73%/10 years). Other hormones/ repoductive factors were not 
significantly associated with change in CSA.  
Few associations were noted with OD in the fully adjusted models [Table 10-5]. 
Compared to nulliparous women, women with  parity ≥ 4 children showed lower increase in OD 
(-0.33) in the transmenopausal period. However this association was not mirrored cumulatively. 
Compared to menearche between 11-12 years, earlier menarche (9-10 years) showed greater 
increase in OD in the pre-transmenopausal period while later menarche (13-14 years) had 
significnatly lower rates of increase in the post-menopausal period. No associations were noted 
in the transmenopausaly or cumulatively. Breastfeeding was associated with greater OD 
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cumulatively (+0.59%/10 years). Doubling of SHBG was associated with increase in OD in the 
transmenopausal period (+0.08%/year) and cumulatively (0.22%/10 years).  
After adjusting for the confounders, later age at menarche (+0.14%/year) was associated 
with greater increases in SM in the post-menopausal period (table 10-6). This association was 
not reflected in the cumulative change. Compared to the 3rd quartile, women with the highest 
quartile of age at FMP had greater loss of SM. Similar to BMD and CSA, doubling of E2 was 
associated with lower transmenopausal loss (+0.17), while FSH doubling was associated with 
greater loss in the transmenopausal period (-0.39) and cumulatively (-2.03%/10 years). Doubling 
of SHBG was associated with greater SM loss in the postmenopausal period (-0.31%/year) and 
cumulatively (-0.90%/10 years). No associations were noted with T. 
In the fully adjusted models, parity ≥4 was associated with greater increase in BR during 
the pre-transmenopausal period, as compared to nulliparous women (table 10-8). No associations 
were noted in the trans- and post-menopausal periods or cumulatively. Later age at first birth was 
associated with greater rates of BR increase in the transmenopausal period (+0.60%/year) and 
cumulatively (+0.25%/10 years).  Ever breastfeeding (+3.87%/10 years) and longer duration of 
breastfeeding (+1.36%/10 years) were associated with greater increase in BR cumulatively. FSH 
doubling was associated with BR increase in the postmenopausal (+0.89%/year) and 
cumulatively (+2.96%/10 year). SHBG doubling was associated with greater in BR in the 
transmenopausal (+0.40%/year), postmenopausal (+0.46%/year) and reflecting (+2.46%/10 
years). No associations were noted with other reproductive factors or hormones.  
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10.5 DISCUSSION 
Our study found that specific reproductive factors like age at first birth, breastfeeding, 
and hormone levels of FSH and SHBG significantly influenced premenopausal hip geometry 
characteristics, and the rate of change of hip geometry measures, particularly around the FMP. 
At baseline, later age at menarche was associated with greater premenopausal OD and SM, while 
later age at last birth was associated with greater premenopausal CSA level. OC use was 
associated with greater premenopausal OD levels. Over the 10 year period, only breastfeeding 
was associated with accelerated decline in BMD, CSA and SM and accelerated increase in OD 
and BR. Longer duration of breastfeeding and later age at first birth were associated with greater 
increase in BR. In the transmenopaual period, later age at first birth and breastfeeding were 
associated with accelerated loss of BMD and greater increase in BR. These associations were 
independent of age, race, BMI, education, physical activity, smoking and diabetes. 
At baseline, doubling of FSH was associated with greater premenopausal OD and BR 
levels while doubling of SHBG was associated with greater premenopausal BR levels. 
Cumulatively over 10 years, doubling of FSH and SHBG were associated with accelerated 
decline in BMD, CSA and SM and accelerated increase in BR. SHBG doubling also showed 
accelerated increase in OD. These associations were independent of age, race, BMI, education, 
physical activity, smoking and diabetes. In the transmenopausal period, doubling of FSH was 
associated with greater decline in BMD and CSA, while doubling of SHBG was associated with 
accelerated increase in OD and BR. Doubling of E2 in the transmenopausal period was 
associated with decelerated decline in CSA and SM. Together, these findings are consistent with 
structural instability and fracture risk accompanying the MT. To the best of our knowledge, no 
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other studies have demonstrated an association between several reproductive factors and level 
and rate of change in hip geometry measures at midlife.  
Both pregnancy and lactation have been known to cause short-term BMD loss (up to 
5%)331,332. During this time, the maternal skeleton compensates for the increased calcium 
demand. In addition to increased caclium absororption from the gut and decreased calcium 
excretion, hormonal changes could result in increased bone resorption. These changes are 
accompanied by increase in parathyroid hormone-related protein levels333 and low estrogen 
levels334. These changes however, may be transient and reversed post-delivery335, typically 
within 6-12 months. However, studies have reported that bone mass may likely not return to 
baseline levels, with longer duration of breastfeeding336. Nevertheless, the long-term effects 
remain ambiguous. While some studies have reported protective337 or no associations338, more 
recent studies have reported unfavorable effects on BMD in later life326.  
Using the Women’s Health Inititative (mean age = 63.6), Crandall et al339, reported 
significant trend for assocation between later age at first birth and greater hip fracture risk, that 
was explained by adjusting for many confounders including age, race, BMI, education and 
physical activity. Contrary to their hypothesis,  breastfeeding was associated with a lower risk of 
hip fractures. The Leisure World Cohort Study340 of older women (mean age = 73 years) 
reported that compared to first birth before 20 years, later age at first birth (30+years) was 
associated with lower risk of spine fracture but not hip fractures. Associations with breastfeeding 
were not assessed. These associations were independent of age, BMI and history of fractures. 
However, important confounders like education and physical activity were not accounted for340. 
Prior work in SWAN reported that, longer duration of breastfeeding and greater parity were 
associated with lower spine BMD and greater impact strength indices respectively235. These 
associations were independent of age, BMI, physical activity and bone adverse medications235. 
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Our results support the hypothesis that pregancy and lactation influence bone re-modelling in 
later life and extend the evidence to hip geometry in midlife.  
MT studies have demonstrated association between higher FSH341,342, lower E2341,342 with 
lower BMD. SHBG, binds to E2 and T and hence lowering the bioavailable E2/T concentrations. 
High SHBG levels are associated with low BMD and an increased risk of fracture130,343,344. 
Interestingly, a prior SWAN study, reported that higher FSH in the pre-trans and 
transmenopausal periods, and lower E2 in the post-menopausal periods were associated with 
faster spine BMD loss. At the femoral neck, transmenopausal high FSH levels were associated 
with greater BMD loss129. Our results mirror these findings and strengthen evidence for 
association between higher FSH and SHBG levels, with greater cortical instability as measured 
by lower BMD, CSA, SM and greater BR.  
Despite the highly regulatory role of estrogen on bone metabolism1, our results did not 
establish significant associations with E2, particularly in the transmenopausal period. Given the 
large variation in E2 during the menstrual cycle129, a single annual measure may therefore not 
refelct these levels adequqtely. Thus it is  likely that FSH is a better measure of ovarian aging 
during this period129, strengthening the eneed for better measures of ovarian aging during the 
MT8. Similarly, no associations were noted with T cumulatively. Some345 but not all studies346 
have shown significant associations between T and BMD. It is likely that androgens play a role 
in bone metabolism as precursors to E2, and not directly347. We also showed that higher SHBG 
was associated with poorer hip geometry, independent of E2 and T (results not shown) levels. 
The exact mechanism of SHBG on the bone is unclear. SHBG levels are directly related to 
estrogen levels and may serve as a proxy for  E2348. Although SHBG has greater affinity for 
androgens then estrogen and is thus a better marker of androgenecity349, our study showed 
SHBG associations were independent of T. Thus, SHBG may act directly via the androgen 
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receptors to activate bone loss350. Together, these findings support the hypothesis that hormonal 
changes during  the MT, produces accelerated changes in hip geometry, increasing its 
susceptibility to fractures. Additionally, no associations were noted with calcium and vitamin D 
for any of the HSA measures (results not shown). 
Our study was limited by HSA estimation from 2 dimensional DXA scans. However, 
HSA estimation from 2D images are comprable with that of QCT measures351. Reproductive 
history was collected via questionnaires, and may be subject to recall bias. Multiple simultaneous 
comparisons may limit the power of statistical inferences. However, the consisitency of results 
across the HSA factors, strenghens our findings to some extent. Blood samples for hormone 
assays were collected in the early follicular phase, which may not be ideal for all the hormones 
mesaured. However, all analyses accounted for cycle day of blood draw. In addition, one of the 
limitations of E2 and T estimation is that it did not detect LLD in the postmenopausal period. 
Strengths of our study include large, multi-ethnic, community-based population with longitudinal 
assessment of FMP, information on an array of reproductive factors and multiple measures of hip 
geometry.  
In conclusion, early life reproductive factors including older age at first birth and 
breastfeeding and greater premenopausal FSH and SHBG levels were associated with levels and 
accelerated unfavourable changes in HSA measures across the MT (10 years). Our results 
strengthen exisiting literature and provide better understanding of reproductive factors 
influencing hip geometry and cortical stability during the MT. Further studies with advanced 
measures of ovarian aging could provide better understanding of the bone health during the MT. 
Early identification of women at risk for accelerated change in bone geometry is important to 
prevent fractures. 
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10.6 TABLES 
Table 10-1: Baseline characteristics of the study population 
Characteristics Baseline (N=1941) 
Age (years)* 46.38(2.67) 
Race/Ethnicity   
        Black N(%) 517(26.55) 
        Chinese N(%) 220(11.30) 
        Japanese N(%) 240(12.33) 
        White N(%) 970(49.82) 
Education    
         High school or less 421(21.62) 
         Greater than high school 1526(78.38) 
Height (cm)* 162.30(6.52) 
Weight (kg)* 72.69(19.33) 
BMI (kg/m2) * 27.55(6.82) 
Smoking status   
        Current smokers N(%) 291(15.06) 
        Past smokers N(%) 494(25.57) 
        Never smokers N(%) 1147(59.37) 
Physical activity score (range 3-14) * 9.95(1.91) 
Age at menarche 12.48(1.45) 
Age at menarche    
          9-10 153(8.14) 
         11-12 802(42.66) 
         13-14 757(40.27) 
         15-16 168(8.94) 
Parity 1.88(1.35) 
Parity    
         Nulliparous 370(19.06) 
         1-3 1374(70.79) 
         4 or more 197(10.15) 
Age at first birth (years)** 25.54(6.15) 
Age at last birth (years)** 30.78(5.83) 
Breastfeeding (YES)** 1077(68.56) 
Duration of breastfeeding (years)** 0.74(1.27) 
Use of oral contraceptive pills (YES) 1431(74.03) 
Estradiol (pg/ml) *** 54.95(33.25, 86.55) 
FSH (mlU/ml) *** 16.2(11.20, 26.5) 
Testosterone (ng/dl) *** 41(29.40, 54.9) 
SHBG (nM) *** 41(28.00, 57.99) 
NN BMD (g/cm2) * 1.06(0.18) 
NN CSA (cm2) * 2.99(0.53) 
NN OD (cm) * 2.96(0.20) 
NN SM (cm3) * 1.36(0.30) 
NN BR * 7.60(1.43) 
*mean ± SD; narrow neck (NN) Bone mineral density (BMD); Cross Sectional Area (CSA); Outer Diameter 
(OD); Section modulus (SM); Buckling Ratio (BR); **excluding nulliparous women; ***Median (Q25, Q75)
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Table 10-2: Cross-sectional association between reproductive factors/hormones and NN HSA measures at baseline 
 Unadjusted model [β(95% CI)] 
Characteristics NN BMD NN CSA NN OD NN SM NN BR 
Age at menarche -0.02(-0.02, -0.01) -0.04(-0.06, -0.02) 0.002(-0.004, 0.01) -0.02(-0.02, -0.01) 0.08(0.03, 0.12) 
Age at menarche  
    9-10 
   11-12 
   13-14 
   15-16 
 
0.07(0.04, 0.10) 
0.03(0.01, 0.05) 
Ref 
-0.01(-0.04, 0.01) 
 
0.19(0.10, 0.28) 
0.09(0.04, 0.15) 
Ref 
-0.04(-0.13, 0.05) 
 
-0.01(-0.05, 0.02) 
0.01(-0.01, 0.03) 
Ref 
0.01(-0.03, 0.04) 
 
0.07(0.02, 0.12) 
0.05(0.02, 0.08) 
Ref 
-0.01(-0.06, 0.04) 
 
-0.29(-0.54, -0.05) 
-0.08(-0.22, 0.06) 
Ref 
0.20(-0.04, 0.44) 
Parity 0.02(0.01, 0.02) 0.04(0.03, 0.06) -0.003(-0.01, 0.003) 0.02(0.01, 0.03) -0.13(-0.18, -0.08) 
Parity  
    Nulliparous 
    1-3 
    4 or more 
 
Ref 
0.02(0.004, 0.04) 
0.08(0.05, 0.11) 
 
Ref 
0.05(-0.01, 0.11) 
0.22(0.13, 0.31) 
 
Ref 
-0.02(-0.04, 0.004) 
-0.004(-0.04, 0.03) 
 
Ref 
0.01(-0.02, 0.05) 
0.09(0.04, 0.14) 
 
Ref 
-0.36(-0.53, -0.20) 
-0.50(-0.74, -0.25) 
Age at first birth (years) A -0.01(-0.01, -0.004) -0.01(-0.02, -0.01) 0.0003(-0.001, 0.002) -0.01(-0.01, -0.003) 0.02(0.01, 0.03) 
Age at last birth (years) A -0.002(-0.003, -0.001) -0.01(-0.01, -0.001) 0.0004(-0.001, 0.002) -0.002(-0.004, 0.001) 0.01(-0.001, 0.02) 
Breastfeeding (YES) A -0.04(-0.05, -0.02) -0.11(-0.17, -0.05) -0.01(-0.03, 0.01) -0.04(-0.07, -0.01) 0.18(0.03, 0.32) 
Duration of breastfeeding A (years) -0.01(-0.01, -0.001) -0.02(-0.04, 0.002) 0.004(-0.003, 0.01) -0.004(-0.01, 0.01) 0.05(0.0002, 0.10) 
Oral contraceptive pills (YES) 0.02(0.003, 0.04) 0.05(-0.0004, 0.11) -0.01(-0.03, 0.01) 0.02(-0.01, 0.05) -0.12(-0.27, 0.02) 
Estradiol (pg/ml) * -0.01(-0.01, 0.001) -0.02(-0.04, 0.003) -0.002(-0.01, 0.01) -0.01(-0.02, 0.0001) 0.03(-0.03, 0.08) 
FSH (mlU/ml) * -0.02(-0.02, -0.01) -0.03(-0.06, -0.01) 0.01(-0.00001, 0.02) -0.01(-0.03, -0.002) 0.13(0.07, 0.19) 
Testosterone (ng/dl) * -0.001(-0.01, 0.01) 0.01(-0.02, 0.04) 0.02(0.003, 0.03) 0.01(-0.005, 0.03) 0.09(0.01, 0.18) 
SHBG (nM) * -0.03(-0.04, -0.02) -0.08(-0.11, -0.05) -0.002(-0.05, 0.01) -0.04(-0.05, -0.02) 0.18(0.10, 0.25) 
SHBGC -0.03(-0.04, -0.02) -0.08(-0.11, -0.05) -0.002(-0.01, 0.001) -0.04(-0.05, -0.02) 0.17(0.09, 0.25) 
 Multivariable model [β (95% CI)] B 
Age at menarche -0.0004(-0.01, 0.005) 0.07(-0.01, 0.02) 0.01(0.001, 0.02) 0.01(0.002, 0.02) 0.03(-0.02, 0.07) 
Age at menarche  
    9-10 
   11-12 
   13-14 
   15-16 
 
-0.001(-0.03, 0.03) 
0.01(-0.01, 0.03) 
Ref 
0.003(-0.02, 0.03) 
 
-0.04(-0.13, 0.05) 
0.02(-0.03, 0.06) 
Ref 
0.01(-0.07, 0.09) 
 
-0.04(-0.07, 0.004) 
-0.01(-0.03, 0.01) 
Ref 
0.01(-0.03, 0.04) 
 
-0.05(-0.10, 0.002) 
0.004(-0.02, 0.03) 
Ref 
0.02(-0.02, 0.07) 
 
0.04(-0.20, 0.27) 
-0.05(-0.18, 0.08) 
Ref 
0.10(-0.12, 0.32) 
Parity 0.0001(-0.01, 0.01) -0.002(-0.02, 0.02) -0.002(-0.01, 0.01) -0.001(-0.01, 0.01) -0.03(-0.08, 0.02) 
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Table 10-2 Continued 
Parity  
    Nulliparous 
    1-3 
    4 or more 
 
Ref 
-0.003(-0.02, 0.02) 
-0.01(-0.04, 0.02) 
 
Ref 
-0.01(-0.06, 0.04) 
-0.02(-0.11, 0.07) 
 
Ref 
-0.003(-0.03, 0.02) 
-0.001(-0.04, 0.04) 
 
Ref 
-0.004(-0.04, 0.03) 
-0.01(-0.06, 0.04) 
 
Ref 
-0.11(-0.26, 0.04) 
-0.08(-0.32, 0.17) 
Age at first birth (years) A 0.001(-0.001, 0.002) 0.003(-0.001, 0.01) 0.001(-0.001, 0.003) 0.001(-0.001, 0.004) 0.0002(-0.01, 0.01) 
Age at last birth (years) A 0.001(-0.001, 0.001) 0.005(0.002, 0.01) 0.002(-0.004, 0.004) 0.002(-0.0003, 0.005) 0.001(-0.01, 0.01) 
Breastfeeding (YES) A 0.01(-0.01, 0.03) 0.02(-0.04, 0.08) -0.02(-0.04, 0.01) -0.01(-0.05, 0.02) -0.02(-0.17, 0.13) 
Duration of breastfeeding A (years) 0.003(-0.003, 0.01) 0.01(-0.01, 0.03) 0.002(-0.01, 0.01) 0.004(-0.01, 0.01) 0.01(-0.03, 0.06) 
Oral contraceptive pills (YES) -0.03(-0.02, 0.01) -0.03(-0.08, 0.02) -0.02(-0.05, -0.002) -0.02(-0.05, 0.01) -0.01(-0.15, 0.13) 
Estradiol (pg/ml) * -0.002(-0.01, 0.004) -0.01(-0.03, 0.01) -0.002(-0.01, 0.01) -0.01(-0.02, 0.005) -0.01(-0.06, 0.04) 
FSH (mlU/ml) * -0.01(-0.01, 0.00001) -0.01(-0.03, 0.01) 0.01(0.0002, 0.02) -0.001(-0.01, 0.01) 0.09(0.03, 0.15) 
Testosterone (ng/dl) * -0.01(-0.02, 0.004) -0.003(-0.03, 0.03) 0.01(-0.001, 0.02) 0.004(-0.01, 0.02) 0.04(-0.04, 0.12) 
SHBG (nM) * -0.01(-0.01, 0.003) -0.01(-0.04, 0.01) 0.01(-0.01, 0.02) -0.004(-0.02, 0.01) 0.04(-0.03, 0.11) 
SHBGC -0.01(-0.01, 0.004) -0.01(-0.04, 0.02) 0.01(-0.01, 0.02) -0.002(-0.02, 0.01) 0.05(-0.03, 0.12) 
*log base 2, adjusted for cycle day; A – excluding nulliparous women; B- adjusted for age, race (ref=Caucasian), site, BMI, education(ref=<=HS), smoking(ref=non-
smoker), physical activity, diabetes (ref=non-diabetic); C- adjusted for log transformed E2; 
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Table 10-3: Rate of change of baseline normalized NN BMD in relation to FMP (fully adjusted models) 
NN BMD1 
Rate of change (slope) in each FMP-defined Phase (%/year) 2 
  
  
  
Cumulative Change
b
 (%)3 
Mean (95% CI), 
-10.67(-11.29, -10.05) 
 
Pre-transmenopause 
(Prior to 2 years before 
FMP) 
Mean
b
 (95% CI), 
-0.001(-0.07, 0.07) 
Transmenopause 
(2 years before to 1 years 
after FMP) 
Mean
b
 (95% CI), 
-1.84(-2.01, -1.66) 
 
Postmenopause 
(1 years after FMP and 
beyond) 
Mean
b
 (95% CI), 
-1.66(-1.82, -1.49) 
Age at menarche -0.02(-0.08, 0.04) 0.06(-0.08, 0.19) 0.06(-0.07, 0.20) 0.30(-0.18, 0.77) 
Age at menarche  
    9-10 
   11-12 
   13-14 
   15-16 
 
0.11(-0.25, 0.47) 
0.02(-0.16, 0.19) 
Ref 
0.03(-0.28, 0.34) 
 
-0.09(-0.87, 0.69) 
-0.09(-0.49, 0.31) 
Ref 
0.09(-0.62, 0.80) 
 
0.08(-0.69, 0.84) 
-0.19(-0.59, 0.21) 
Ref 
-0.22(-0.91, 0.46) 
 
0.02(-2.73, 2.77) 
-0.69(-2.09, 0.70) 
Ref 
0.02(-2.46, 2.43) 
Parity -0.03(-0.09, 0.03) -0.03(-0.16, 0.11) -0.06(-0.20, 0.07) -0.29(-0.75, 0.18) 
Parity      
    Nulliparous 
    1-3 
    4 or more 
Ref 
-0.01(-0.21, 0.20) 
-0.29(-0.60, 0.03) 
Ref 
-0.09(-0.54, 0.35) 
0.04(-0.67, 0.75) 
Ref 
0.07(-0.39, 0.53) 
-0.35(-1.12, 0.42) 
Ref 
-0.26(-1.82, 1.30) 
-1.11(-3.63, 1.41) 
Age at first birth (years) A 0.001(-0.01, 0.02) -0.04(-0.07, -0.004) 0.03(-0.01, 0.06) -0.10(-0.22, 0.02) 
Age at last birth (years) A -0.01(-0.02, 0.01) -0.03(-0.06, 0.01) 0.01(-0.02, 0.04) -0.10(-0.22, 0.02) 
Breastfeeding (YES) A -0.04(-0.24, 0.17) -0.50(-0.95, -0.06) -0.06(-0.49, 0.36) -2.21(-3.72, -0.71) 
Duration of breastfeeding A 
(years) -0.03(-0.09, 0.03) -0.05(-0.19, 0.10) -0.07(-0.23, 0.10) -0.37(-0.91, 0.16) 
Oral contraceptive pills (YES) 0.05(-0.12, 0.22) -0.13(-0.52, 0.27) 0.15(-0.24, 0.54) -0.10(-1.47, 1.28) 
Estradiol (pg/ml) B 0.01(-0.07, 0.09) 0.10(-0.01, 0.21) -0.15(-0.38, 0.07) 0.11(-0.38, 0.60) 
FSH (mlU/ml) B 0.03(-0.06, 0.12) -0.30(-0.45, -0.15) 0.01(-0.23, 0.24) -1.12(-1.75, -0.50) 
Testosterone (ng/dl) B -0.09(-0.20, 0.02) 0.12(-0.09, 0.32) -0.05(-0.27, 0.18) 0.20(-0.47, 0.87) 
SHBG (nM) B 0.01(-0.08, 0.10) -0.13(-0.29, 0.04) -0.18(-0.37, 0.004) -0.86(-1.39, -0.34) 
SHBGC -0.002(-0.09, 0.09) -0.11(-0.28, 0.05) -0.19(-0.38, 0.002) -0.84(-1.37, -0.31) 
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Table 10-4: Rate of change of baseline normalized NN CSA in relation to FMP (fully adjusted models) 
NN CSA1 
Rate of change (slope
a
) in each FMP-defined Phase (%/year) 2   
  
  
Cumulative Change
b
 (%)3 
Mean
b
 (95% CI), 
-9.01(-9.63, -8.39) 
 
Pre-transmenopause 
(Prior to 2 years before 
FMP) 
Mean
b
 (95% CI) 
-0.003(-0.07, 0.07) 
Transmenopause 
(2 years before to 1 years 
after FMP) 
Mean
b
 (95% CI) 
-1.45(-1.63, -1.27) 
Postmenopause 
(1 years after FMP and 
beyond) 
Mean
b
 (95% CI) 
-1.59(-1.76, -1.42) 
Age at menarche -0.03(-0.09, 0.03) 0.07(-0.07, 0.21) 0.11(-0.03, 0.21) 0.43(-0.06, 0.91) 
Age at menarche  
    9-10 
   11-12 
   13-14 
   15-16 
 
0.22(-0.16, 0.59) 
0.04(-0.14, 0.22) 
Ref 
0.07(-0.25, 0.39) 
 
-0.30(-1.12, 0.51) 
-0.04(-0.46, 0.38) 
Ref 
0.12(-0.62, 0.86) 
 
-0.04(-0.87, 0.79) 
-0.31(-0.74, 0.12) 
Ref 
-0.24(-0.99, 0.50) 
 
-0.86(-3.69, 1.97) 
-0.70(-2.14, 0.73) 
Ref 
0.14(-2.38, 2.66) 
Parity -0.02(-0.08, 0.04) -0.06(-0.20, 0.08) -0.05(-0.20, 0.10) -0.37(-0.85, 0.11) 
Parity      
    Nulliparous 
    1-3 
    4 or more 
Ref 
-0.004(-0.21, 0.20) 
-0.23(-0.54, 0.09) 
Ref 
-0.17(-0.63, 0.30) 
-0.26(-1.00, 0.48) 
Ref 
0.03(-0.47, 0.53) 
-0.22(-1.05, 0.62) 
Ref 
-0.22(-1.05, 0.62) 
-0.61(-2.22, 0.99) 
Age at first birth (years) A 0.0005(-0.01, 0.02) -0.04(-0.07, -0.00001) 0.02(-0.01, 0.06) -0.10(-0.22, 0.02) 
Age at last birth (years) A -0.01(-0.02, 0.01) -0.03(-0.07, 0.01) 0.01(-0.02, 0.05) -0.01(-0.23, 0.02) 
Breastfeeding (YES) A -0.003(-0.21, 0.20) -0.40(-0.87, 0.06) -0.10(-0.55, 0.35) -1.82(-3.37, -0.27) 
Duration of breastfeeding A 
(years) -0.03(-0.08, 0.03) -0.03(-0.19, 0.12) -0.08(-0.26, 0.10) -0.33(-0.89, 0.23) 
Oral contraceptive pills (YES) 0.06(-0.12, 0.23) -0.16(-0.57, 0.26) 0.20(-0.22, 0.63) -0.11(-1.53, 1.32) 
Estradiol (pg/ml) B 0.004(-0.08, 0.09) 0.14(0.03, 0.26) -0.15(-0.39, 0.09) 0.27(-0.24, 0.79) 
FSH (mlU/ml) B 0.03(-0.06, 0.13) -0.28(-0.44, -0.13) -0.05(-0.30, 0.21) -1.16(-1.81, -0.51) 
Testosterone (ng/dl) B -0.09(-0.20, 0.02) 0.11(-0.10, 0.32) -0.06(-0.30, 0.18) 0.14(-0.54, 0.83) 
SHBG (nM) B -0.01(-0.10, 0.08) -0.05(-0.22, 0.13) -0.22(-0.42, -0.02) -0.65(-1.19, -0.11) 
SHBGC -0.02(-0.11, 0.08) -0.04(-0.21, 0.14) -0.22(-0.43, -0.02) -0.62(-1.17, -0.08) 
1 adjusted for site, baseline value and DXA scanner, race, education, BMI, diabetes, smoking, physical activity; 2 Rate of change (slope) in percentage of baseline value of 
the index of interest. Negative values mean faster decline, and positive values mean slower decline; 3 Cumulative change during the years spanning the final menstrual 
period [Median time (years) of first visit – Median time (years) of last visit]. A – excluding nulliparous women; Blog base 2, adjusted for cycle day; C- adjusted for log 
transformed E2 
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Table 10-5: Rate of change of baseline normalized NN OD in relation to FMP (fully adjusted models) 
NN OD1 
Rate of change (slope
a
) in each FMP-defined Phase (%/year) 2   
  
  
Cumulative Change
b
 (%)3 
Mean
b
 (95% CI), 
1.95(1.73, 2.18) 
Pre-transmenopause 
(Prior to 2 years before 
FMP) 
Mean
b
 (95% CI), 
-0.01(-0.03, 0.01) 
Transmenopause 
(2 years before to 1 years 
after FMP) 
Mean
b
 (95% CI), 
0.44(0.38, 0.50) 
Postmenopause 
(1 years after FMP and 
beyond) 
Mean
b
 (95% CI), 
0.11(0.06, 0.16) 
Age at menarche -0.01(-0.02, 0.01) 0.01(-0.04, 0.06) 0.05(0.003, 0.09) 0.12(-0.06, 0.31) 
Age at menarche  
    9-10 
   11-12 
   13-14 
   15-16 
 
0.10(0.002, 0.19) 
Ref 
0.02(-0.03, 0.06) 
0.03(-0.05, 0.11) 
 
-0.18(-0.47, 0.10) 
Ref 
0.06(-0.09, 0.20) 
0.05(-0.21, 0.30) 
 
-0.13(-0.38, 0.12) 
Ref 
-0.15(-0.28, -0.01) 
-0.04(-0.27, 0.19) 
 
-0.79(-1.85, 0.27) 
Ref 
-0.02(-0.57, 0.52) 
0.16(-0.79, 1.11) 
Parity 0.01(-0.01, 0.02) -0.04(-0.09, 0.01) 0.03(-0.02, 0.08) -0.10(-0.28, 0.08) 
Parity      
    Nulliparous 
    1-3 
    4 or more 
Ref 
0.01(-0.04, 0.07) 
0.05(-0.03, 0.13) 
Ref 
-0.11(-0.27, 0.06) 
-0.33(-0.59, -0.08) 
Ref 
0.01(-0.14, 0.17) 
0.16(-0.10, 0.42) 
Ref 
-0.37(-0.98, 0.23) 
-0.92(-1.90, 0.06) 
Age at first birth (years) A -0.0005(-0.005, 0.004) 0.003(-0.01, 0.02) -0.005(-0.02, 0.01) 0.002(-0.04, 0.05) 
Age at last birth (years) A 0.0001(-0.004, 0.004) -0.004(-0.02, 0.01) 0.004(-0.01, 0.02) -0.01(-0.05, 0.04) 
Breastfeeding (YES) A 0.03(-0.02, 0.09) 0.11(-0.06, 0.27) 0.05(-0.09, 0.19) 0.59(0.03, 1.15) 
Duration of breastfeeding A 
(years) 0.01(-0.01, 0.02) 0.01(-0.04, 0.07) 0.02(-0.03, 0.07) 0.10(-0.10, 0.29) 
Oral contraceptive pills (YES) -0.01(-0.05, 0.04) -0.03(-0.17, 0.12) 0.06(-0.07, 0.19) 0.003(-0.53, 0.54) 
Estradiol (pg/ml) B -0.002(-0.02, 0.02) 0.03(-0.01, 0.08) -0.01(-0.10, 0.07) 0.11(-0.08, 0.29) 
FSH (mlU/ml) B -0.01(-0.03, 0.02) 0.03(-0.03, 0.09) -0.02(-0.10, 0.06) 0.07(-0.17, 0.30) 
Testosterone (ng/dl) B 0.01(-0.02, 0.03) -0.03(-0.09, 0.03) 0.02(-0.05, 0.08) -0.08(-0.28, 0.13) 
SHBG (nM) B -0.01(-0.04, 0.01) 0.09(0.03, 0.15) -0.04(-0.10, 0.03) 0.24(0.04, 0.44) 
SHBGC -0.01(-0.04, 0.01) 0.09(0.03, 0.15) -0.04(-0.10, 0.03) 0.24(0.04, 0.44) 
1 adjusted for site, baseline value and DXA scanner, race, education, BMI, diabetes, smoking, physical activity; 2 Rate of change (slope) in percentage of baseline value of 
the index of interest. Negative values mean faster decline, and positive values mean slower decline; 3 Cumulative change during the years spanning the final menstrual 
period [Median time (years) of first visit – Median time (years) of last visit]. A – excluding nulliparous women; Blog base 2, adjusted for cycle day; C- adjusted for log 
transformed E2 
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Table 10-6: Rate of change of baseline normalized NN SM in relation to FMP (fully adjusted models) 
NN SM1 
Rate of change (slope
a
) in each FMP-defined Phase (%/year) 2   
  
  
Cumulative Change
b
 (%)3 
Mean
b
 (95% CI), 
-7.03(-7.80, -6.25) 
Pre-transmenopause 
(Prior to 2 years before 
FMP) 
Mean
b
 (95% CI), 
-0.01(-0.11, 0.09) 
Transmenopause 
(2 years before to 1 years 
after FMP) 
Mean
b
 (95% CI), 
-1.09(-1.32, -0.86) 
Postmenopause 
(1 years after FMP and 
beyond) 
Mean
b
 (95% CI), 
-1.33(-1.54, -1.11) 
Age at menarche -0.05(-0.14, 0.04) 0.09(-0.10, 0.28) 0.14(-0.05, 0.32) 0.54(-0.08, 1.16) 
Age at menarche  
    9-10 
   11-12 
   13-14 
   15-16 
 
0.47(-0.07, 1.01) 
-0.02(-0.28, 0.24) 
Ref 
0.09(-0.38, 0.55) 
 
-0.71(-1.80, 0.38) 
-0.05(-0.61, 0.51) 
Ref 
-0.05(-1.04, 0.94) 
 
-0.09(-1.14, 0.95) 
-0.34(-0.88, 0.21) 
Ref 
-0.22(-1.16, 0.72) 
 
-2.07(-5.69, 1.55) 
-0.90(-2.73, 0.94) 
Ref 
-0.47(-3.68, 2.74) 
Parity -0.03(-0.12, 0.06) -0.11(-0.29, 0.08) -0.01(-0.19, 0.18) -0.50(-1.11, 0.10) 
Parity      
    Nulliparous 
    1-3 
    4 or more 
Ref 
0.02(-0.29, 0.32) 
-0.32(-0.79, 0.15) 
Ref 
-0.43(-1.06, 0.19) 
-0.64(-1.62, 0.35) 
Ref 
0.06(-0.57, 0.69) 
0.18(-0.87, 1.23) 
Ref 
-1.57(-3.62, 0.47) 
-2.84(-6.14, 0.47) 
Age at first birth (years) A 0.002(-0.02, 0.03) -0.03(-0.08, 0.02) 0.02(-0.02, 0.06) -0.08(-0.23, 0.08) 
Age at last birth (years) A -0.01(-0.03, 0.01) -0.02(-0.07, 0.03) 0.01(-0.03, 0.06) -0.07(-0.23, 0.08) 
Breastfeeding (YES) A 0.08(-0.24, 0.40) -0.49(-1.10, 0.12) 0.18(-0.38, 0.74) -1.45(-3.41, 0.51) 
Duration of breastfeeding A 
(years) -0.02(-0.10, 0.07) -0.03(-0.23, 0.18) 0.04(-0.17, 0.26) -0.06(-0.76, 0.64) 
Oral contraceptive pills (YES) 0.13(-0.14, 0.39) -0.25(-0.80, 0.30) -0.08(-0.61, 0.45) -0.90(-2.72, 0.91) 
Estradiol (pg/ml) B 0.02(-0.10, 0.15) 0.17(0.005, 0.33) -0.24(-0.54, 0.06) 0.24(-0.43, 0.92) 
FSH (mlU/ml) B 0.03(-0.11, 0.17) -0.39(-0.61, -0.17) -0.27(-0.59, 0.04) -2.03(-2.86, -1.19) 
Testosterone (ng/dl) B -0.11(-0.28, 0.05) 0.20(-0.09, 0.50) -0.12(-0.43, 0.18) 0.34(-0.57, 1.26) 
SHBG (nM) B -0.04(-0.17, 0.10) -0.05(-0.29, 0.19) -0.31(-0.56, -0.05) -0.87(-1.60, -0.15) 
SHBGC -0.05(-0.18, 0.09) -0.03(-0.27, 0.21) -0.31(-0.56, -0.06) -0.83(-1.56, -0.11) 
1 adjusted for site, baseline value and DXA scanner, race, education, BMI, diabetes, smoking, physical activity; 2 Rate of change (slope) in percentage of baseline value of 
the index of interest. Negative values mean faster decline, and positive values mean slower decline; 3 Cumulative change during the years spanning the final menstrual 
period [Median time (years) of first visit – Median time (years) of last visit]. A – excluding nulliparous women; Blog base 2, adjusted for cycle day; C- adjusted for log 
transformed E2 
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Table 10-7: Rate of change of baseline normalized NN BR in relation to FMP (fully adjusted models) 
NN BR1 
Rate of change (slope
a
) in each FMP-defined Phase (%/year) 2   
  
  
Cumulative Change
b
 (%)3 
Mean
b
 (95% CI), 
19.84(18.58, 21.09) 
Pre-transmenopause 
(Prior to 2 years before 
FMP) 
Mean
b
 (95% CI), 
0.05(-0.02, 0.13) 
Transmenopause 
(2 years before to 1 years 
after FMP) 
Mean
b
 (95% CI), 
3.02(2.71, 3.33) 
Postmenopause 
(1 years after FMP and 
beyond) 
Mean
b
 (95% CI), 
3.83(3.39, 4.26) 
Age at menarche 0.03(-0.03, 0.10) -0.15(-0.36, 0.06) -0.09(-0.40, 0.22) -0.70(-1.65, 0.26) 
Age at menarche  
    9-10 
   11-12 
   13-14 
   15-16 
 
0.02(-0.37, 0.41) 
-0.04(-0.23, 0.14) 
Ref 
-0.06(-0.39, 0.28) 
 
-0.39(-1.58, 0.80) 
0.49(-0.12, 1.11) 
Ref 
-0.15(-1.24, 0.93) 
 
-0.12(-1.91, 1.67) 
0.42(-0.50, 1.34) 
Ref 
0.55(-1.02, 2.11) 
 
-1.76(-7.26, 3.74) 
2.73(-0.07, 5.52) 
Ref 
0.37(-4.52, 5.25) 
Parity 0.05(-0.02, 0.12) -0.08(-0.29, 0.12) 0.20(-0.11, 0.52) 0.17(-0.78, 1.12) 
Parity      
    Nulliparous 
    1-3 
    4 or more 
Ref 
0.05(-0.17, 0.28) 
0.43(0.09, 0.78) 
Ref 
-0.07(-0.76, 0.62) 
-0.54(-1.64, 0.56) 
Ref 
0.02(-1.04, 1.08) 
0.66(-1.13, 2.45) 
Ref 
-0.13(-3.31, 3.04) 
0.03(-5.18, 5.24) 
Age at first birth (years) A -0.001(-0.02, 0.02) 0.06(0.01, 0.11) 0.01(-0.07, 0.09) 0.25(0.02, 0.48) 
Age at last birth (years) A 0.02(-0.00001, 0.03) 0.02(-0.04, 0.07) 0.04(-0.04, 0.12) 0.17(-0.07, 0.41) 
Breastfeeding (YES) A 0.14(-0.10, 0.38) 0.44(-0.24, 1.11) 0.92(-0.05, 1.90) 3.87(0.93, 6.81) 
Duration of breastfeeding A 
(years) 0.06(-0.01, 0.12) 0.14(-0.09, 0.36) 0.34(-0.06, 0.75) 1.36(0.26, 2.45) 
Oral contraceptive pills (YES) -0.02(-0.21, 0.17) -0.32(-0.93, 0.29) -0.0003(-0.91, 0.91) -1.33(-4.11, 1.46) 
Estradiol (pg/ml) B -0.08(-0.17, 0.01) 0.03(-0.12, 0.19) -0.29(-0.82, 0.24) -0.61(-1.69, 0.47) 
FSH (mlU/ml) B 0.04(-0.06, 0.14) 0.21(-0.004, 0.42) 0.89(0.32, 1.46) 2.96(1.39, 4.00) 
Testosterone (ng/dl) B 0.05(-0.07, 0.17) -0.02(-0.32, 0.28) -0.11(-0.62, 0.40) -0.20(-1.50, 1.09) 
SHBG (nM) B -0.04(-0.14, 0.06) 0.40(0.15, 0.65) 0.46(0.04, 0.88) 2.43(1.40, 3.46) 
SHBGC -0.03(-0.13, 0.07) 0.39(0.14, 0.64) 0.45(0.03, 0.87) 2.39(1.36, 3.41) 
1 adjusted for site, baseline value and DXA scanner, race, education, BMI, diabetes, smoking, physical activity; 2 Rate of change (slope) in percentage of baseline value of 
the index of interest. Negative values mean faster decline, and positive values mean slower decline; 3 Cumulative change during the years spanning the final menstrual 
period [Median time (years) of first visit – Median time (years) of last visit]. A – excluding nulliparous women; Blog base 2, adjusted for cycle day; C- adjusted for log 
transformed E2 
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10.7 SUPPLEMENAL TABLE AND FIGURE 
Supplemental Table 10-8: Correlation between reproductive factors, hormones and HSA measures 
 Menarche parity Age 
at 
first 
birth 
Age 
at last 
birth 
Ever 
breastfed 
Duration 
of breast- 
feeding 
Ever 
OCP 
Average 
E2 
FSH T SHBG BMD CSA Width Section 
modulus 
Buckling 
ratio 
Menarche 1                
parity -0.03 1               
Age at first 
birth 
0.02 -0.41 1              
Age at last 
birth 
0.004 0.18 0.66 1             
Ever 
breastfed 
-0.003 0.03 0.36 0.36 1            
Duration of 
breastfeeding 
-0.02 0.27 0.18 0.33 0.46 1           
Ever OCP -0.04 0.005 -0.09 -0.07 -0.07 -0.08 1          
Average E2 -0.02 0.01 -0.01 0.01 -0.01 0.02 -0.02 1         
FSH 0.03 -0.06 0.05 -0.01 0.01 -0.0001 -0.02 -0.4 1        
T -0.04 -0.01 0.01 0.01 -0.001 0.003 0.02 0.04 -0.08 1       
SHBG 0.05 -0.02 0.02 0.03 -0.001 0.02 -0.07 0.21 0.06 -0.05 1      
BMD -0.09 0.11 -0.19 -0.08 -0.11 -0.05 0.07 0.1 -0.33 0.01 -0.15 1     
CSA -0.09 0.1 -0.16 -0.06 -0.1 -0.04 0.07 0.08 -0.3 0.01 -0.15 0.93 1    
Width -0.01 -0.02 0.05 0.03 -0.0004 0.04 -0.0008 -0.04 0.05 -0.004 0.004 -0.1 0.27 1   
Section 
modulus 
-0.08 0.07 -0.11 -0.04 -0.07 -0.02 0.06 0.05 -0.24      
0.004 
-0.12 0.77 0.93 0.48 1  
Buckling 
ratio 
0.04 -0.07 0.14 0.07 0.08 0.06 -0.05 -0.13 0.34 
-0.004 
0.14 -0.78 -0.60 0.44 -0.41 1 
*bold if p<0.05 and correlation coefficient > |0.1| 
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Supplemental Figure 10-1: Analysis sample derivation 
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11.0  DISCUSSION 
11.1 SUMMARY, CONCLUSIONS AND FUTURE RESEARCH 
The main objective of the dissertation was to investigate the role of reproductive factors 
and sex-hormones on musculoskeletal aging as characterized by decline in physical functioning, 
risk of hip OA and change in bone geometry in later life. In a cohort of Caucasian women (65-80 
years) followed over 20 years, we found that early life reproductive factors like later age at 
menarche, greater parity and breastfeeding were associated with a greater likelihood of 
maintaining grip strength over time. Conversely, women who underwent hysterectomy or 
oophorectomy were more likely to experience accelerated loss of grip strength. These 
associations were independent of age, education, BMI and physical activity. No associations of 
reproductive factors with chair stand time or grip strength. These findings are in support of our 
hypothesis that reproductive factors are associated with level and rate of change of physical 
function in later life. Lifestyle factors associated with child rearing could contribute to the 
association between perinatal factors and grip strength.  
In our second paper, we examined the associations between reproductive factors and risk 
of RHOA. Contrary to existing literature on knee OA, we found that greater parity and 
breastfeeding were associated with lower risk of incident and total RHOA in the SOF Caucasian 
population. No associations were noted with the other reproductive factors. These associations 
were independent of age, education, BMI and physical activity. We postulate that with the 
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increase in weight during pregnancy, the center of gravity shifts forwards and upwards, 
increasing the load at the knee joint and decreasing the load on the hip joint309. In addition, anti-
inflammatory properties of breastfeeding may protect women against RHOA. Together, these 
findings support our hypothesis that reproductive factors are associated with joint health in later 
life.  
Finally, we investigated the associations of reproductive factors, sex hormones with the 
level and rate of change of hip geometry as measured by HSA. At baseline, later age at last birth 
was associated with greater NN CSA while OC use was associated with lower OD. Over the 
course of the MT, few factors were associated with change in hip geometry. Breastfeeding was 
associated with faster decline in BMD, and CSA and increase in OD and BR over the 10-year 
period. Later age at first birth was associated with an increased trans-menopausal decline in 
BMD, CSA and increase in BR. Doubling of FSH and SHBG were associated with faster decline 
in BMD, CSA and SM along with accelerated increase in BR over the 10-year period. These 
associations were independent of age, race, education, BMI, smoking, physical activity and 
diabetes. These findings parallel the changes in aBMD129 and support the hypothesis that 
reproductive factors are associated with level and rate of change of hip geometry in midlife 
women.  
The findings from these papers shed light on the role of reproductive factors on 
musculoskeletal aging. Using a life course approach, we demonstrated the associations between 
important early life reproductive events (menarche, parity, breastfeeding and surgical 
interventions like hysterectomy and oophorectomy) with later life changes in bone and muscle 
health. In addition to lifestyle factors related to child rearing, changes in body composition, 
hormones and immunological pathways may play important roles in mediating these 
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associations. However, our understanding of these mechanisms is limited. Life course 
epidemiology is an emerging field of research. Attempts are underway to understand the life 
course origins of disease and age-related disorders in later life. Therefore, future studies are 
needed to better understand the underlying pathways relating reproductive health with 
musculoskeletal health in later life. With a clear understanding of mechanistic pathways, it may 
be possible to use these reproductive factors as markers for successful musculoskeletal aging. 
Through this dissertation, we demonstrated that few select reproductive factors were 
associated with musculoskeletal health and aging in later life. While greater parity and 
breastfeeding were associated with greater likelihood of maintaining grip strength and lower risk 
of hip OA in older SOF women, later age at first birth and breastfeeding were associated with 
unfavorable trans-menopausal changes in hip geometry measures in midlife SWAN women. 
Despite the significant non-linear trend, few parity groups demonstrated significant association 
with the risk of radiographic hip OA. In addition to perinatal factors, later life surgeries like 
hysterectomy and oophorectomy were associated with lower grip strength in SOF population. 
Barring the perinatal factors, particularly breastfeeding, no common factors were noted across 
the 3 papers. It is important to note that due to cohort differences in the distribution of parity in 
the 3 studies, parity was assessed differently. SWAN women were younger and more likely to 
have fewer children compared to the much older SOF women. In addition, the lack of 
associations between BMI/ weight/ change in BMI or weight was not associated with risk of 
RHOA. Given these factors, the results from the 3 studies should be interpreted with some 
caution and are not comparable. To increase the generalizability of these results, similar studies 
with long durations of follow up are needed to understand the effect of the reproductive factors 
on musculo-skeletal functioning in later life in other multi-ethnic populations across the globe. 
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These results shall aid in not only understanding the effect of reproductive health in later life but 
also in deducing meaningful clinical implications and intervention design.  
It is important to weight these results against the limitations. Due to availability of 
reproductive information, the associations of reproductive health with functional decline and 
RHOA were limited to Caucasian women. These findings may not be generalizable to other 
studies. Additionally, reproductive data was collected from questionnaires and may be subject to 
recall bias. However, studies have reported high reliability for reproductive health collected 
through questionnaires352. Given the vast number of reproductive factors that were assessed 
independently, it is likely that some of the results were just a result of chance i.e. multiplicity. 
However, consistent associations with specific reproductive factors across the studies, suggests 
little role of chance. The strengths of our studies include large sample sizes, information on 
various reproductive factors, and objective or radiological outcome measures obtained over long 
follow up periods. 
11.2 OVERALL IMPACT AND PUBLIC HEALTH SIGNIFICANCE 
In 2013, the World Health Organization (WHO) recommended an integrated and life 
course approach to health and disease in women353. In accordance, our study aimed at 
understanding associations between reproductive factors from menarche to menopause with 
changes in bone and muscle in later life. This dissertation focused on understanding the long-
term effects of reproductive health on musculo-skeletal aging. To the best of our knowledge, this 
is the first study to assess and compare all the reproductive milestones in relation to 
109 
musculoskeletal aging. The novelty of the study lies in the life course approach to identify the 
reproductive risk factors for musculoskeletal aging and disease. Through this, we hoped to –  
1. Understand the associations between of multiple factors of reproductive health and 
musculoskeletal health independent of confounders like age, BMI, smoking and physical activity 
2. Characterize the effects of these reproductive factors on both structural and functional aspects 
of musculoskeletal health 
3. Understand the effect of reproductive and ovarian aging on the musculoskeletal system 
beyond chronological aging 
The population of the world in increasing rapidly. With this increase in the older 
population, higher population of women are more likely to suffer from disability and functional 
limitations. These factors represent a major healthcare and economic burden. Expenditure on 
musculoskeletal disorders are greater than cost of cardiovascular, breast cancer and stroke 
combined354. Thus, it is important to understand the risk factors and underlying mechanisms 
contributing to functional decline, and disability. Major consequences of these limitations 
include morbidity and mortality.  
The work from this dissertation has important public health implications. Using a life-
course approach, our findings established associations between reproductive health and 
musculoskeletal aging. Accumulation of physiological insults could contribute to poor 
musculoskeletal health in later life. Understanding the underlying mechanisms could help 
identify these “at risk” women for future disability and design appropriate interventions to 
prevent functional decline and disability, and subsequently lower the healthcare expenditures.  
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